Breathing fire into targeted therapies at ASH23

In our latest Preview from the American Society of Hematology, we’re using the dragon’s…

November 30, 2023

Seeing the wood from the trees at ASH23

How a competitive landscape can change drastically over a short time

November 27, 2023

Insights on an emerging competitor landscape

What's next beyond BTK inhibition in lymphomas and CLL?

November 21, 2023

Wielding AI’s power for scientific good

Pulling disparate sources together to develop a more optimised approach to targeting oncoproteins

November 16, 2023

Wrestling an intractable cancer target into submission

There is beauty in drugging intractable targets

November 15, 2023

Unveiling the science behind a new IO strategy

A look at the potential missing piece in making bispecifics even better

November 10, 2023

Setting the scene

Spotting the winners and losers in the gastric cancer niche

November 8, 2023

SITC23 Scorecard for emerging novel IO therapies

W2W4 at SITC23 - 10 emerging areas to pay attention to in IO

November 6, 2023

Unexpected developments at SITC23

Some up and coming novel ADCs to watch out for

November 6, 2023

Tagging the Donkey

Will in vivo CAR-T cell therapies go prime time?

November 2, 2023

Pointing the IO way

Eight key areas to watch out for at SITC 2023!

October 27, 2023

The Fall and Rise of Essa Pharma

Out of the ashes, a new phoenix can rise

October 23, 2023

Process is power

Dawn of a new IO era at ESMO23?

October 23, 2023

Who’s waving the flag at ESMO 2023?

Red and green flags on certain trials at ESMO23

October 22, 2023

How bispecific antibodies are reshaping cancer treatment

After a long wait, finally some encouraging data in advanced solid tumours!

October 21, 2023

The guardian of the genome

Important new findings on the cell therapy front

October 19, 2023

Scaling the ESMO23 ramparts

8 targets to watch out for at ESMO23

October 17, 2023

Precision Targeting of Elusive Cancer Oncogenes

More gems from the TARGETS23 poster halls

October 16, 2023

How to Knock Out Cancer’s Backup Plan

Searching for well tolerated combinations in the KRAS niche

October 13, 2023

The Next Frontier

From small acorns, so oak trees grow

October 12, 2023

What to watch out for at TARGETS23 – Part 2

What to watch out for in DDR, epigenetic therapies, and other hot topics

October 11, 2023

Ever Decreasing Circles

From epigenetics to SHP2, a look at various upcoming presentations this month

October 5, 2023

ESMO Preview 2 – Making sense of controversy

There's a huge surge in ADCs in the clinic but how many will make an impact?

October 2, 2023

ESMO23 Preview 1 – Hype over Hope?

Parsing cancer research hype at ESMO23

September 27, 2023

Early stage oncology data of interest in TARGETS23 preview

A look at some hot topics from the TARGETS/TRIPLE meeting in Boston

September 20, 2023

Gunning for new targets, new approaches

From CAR-T cells to protein degradation

September 19, 2023

What science tells us about future directions in lung cancer

What we can learn from scientific talks at WCLC in order to improve clinical development

September 13, 2023

Kicking KRAS to the kerb

Review of new KRAS inhibitor studies including G12C and G12D

September 11, 2023

WCLC23 – SCLC highlights and lowlights

Seeing the wood from the trees in ES-SCLC developments

September 11, 2023

Adding up the evidence

Early-stage agents in development for multiple myeloma - hit or miss?

September 7, 2023

Targeted Therapy Trials: Why some drug developers keep missing the mark

Do we need to pay more attention to the underlying biology in aggressive lymphomas?

September 5, 2023

Taking Myeloma by the Horns

Challenges and opportunities in the myeloma niche

August 31, 2023

New Developments in Targeting Pancreatic Cancer

Important new preclinical data sets the scene for PDAC

August 30, 2023

Exploring unexpected targets in brain tumours

As we head into the long August Bank Holiday and Labor Day celebrations, I wanted to offer some…

August 24, 2023

The ADC merry-go-round

Part 2 of our WCLC 2023 Previews

August 22, 2023

The scudding clouds of freedom

Finding the sweetspot in early stage cancer drug development

August 16, 2023

A flurry of new biomarkers are coming to the fore

How exploratory new biomarkers are paving the way

August 14, 2023

Cracking the Code on a Novel Cancer Target

One of the challenging and frustrating aspects of oncology drug development is in knowing a target is…

August 10, 2023

Playing with fire

Some perspectives on the balancing act required between stimulus and response

August 9, 2023

Opening the solid tumour CAR-T treasure chest

Progress report on a varied China based CAR-T cell program

August 4, 2023

Wow, just wow!

When an established concept is finally coming of age with new colours...

August 3, 2023

An emerging opportunity in the CAR-T cell therapy space

Taking a different approach to CAR design with some positive data to show for it

August 2, 2023

What’s hot in lung cancer?

Preview - Wwat to watch for at WCLC23

July 27, 2023

Important and novel research to be inspired by

Highlighting some outstanding research to take note of

July 25, 2023

Summer Shorts

Have we reached the point where Pharmaland cooks the golden goose?

July 20, 2023

Digging deep for answers

Finding rare thistles in the fields

July 19, 2023

Summer fun with AI

How we can use AI to improve scientific writing and reports

July 13, 2023

Cut and run

A potentially novel approach for some advanced breast cancers

July 11, 2023

A window into the future of IO

Where a forgotten sostimulator may hold the key to new developments

June 28, 2023

Standing out from the crowd in AML

Encouraging new developments in the CAR-NK niche

June 27, 2023

Next generation CAR-T cell therapies for the future

From autologous to gene edited CARs and much in between - W2W4 on 14 next gen products

June 22, 2023

An alternative perspective on Hodgkins lymphoma

There's much more to think about implications from readouts than the scoreboard

June 19, 2023

How Tec kinases could make a difference in PTCL at iCML23

New developments in hard to treat refractory PTCL

June 15, 2023

Stacking up the clinical evidence at ASCO23

We put 10 clinical trials through their paces to ascertain whether they were hype or not

June 13, 2023

An under-rated gem at ASCO23

Tackling intractable cancers with a novel and creative approach to the problem

June 8, 2023

Making sense of all the TIGIT data at ASCO23

Continuing our coverage of the annual meeting of ASCO in Chicago I felt compelled to review the actual…

June 6, 2023

A look at early stage trials debuting at ASCO23

What do three phase 1 and one phase 2 trials tell us about future development?

June 5, 2023

Divvying it up at ASCO23

A look at 4 trials with largely unexpected results

June 4, 2023

Are the lions roaring in Chicago?

Highlights from Day 1 at ASCO23

June 3, 2023

Battle lines drawn in adjuvant breast cancer

How does the NATALEE trial stack up in adjuvant HR+/HER2- breast cancer?

June 2, 2023

Intriguing progress on the KRAS front

Novel KRAS developments to watch out for

June 1, 2023

On TIGIT, ADCs, and other stories

Some ASCO23 abstracts to watch out for and why

May 31, 2023

Chemistry in context – next generation cell therapies

Opportunities and challenges abund for several next-gen CAR-T cell therapies

May 25, 2023

From far away you see more

Next generation CAR-T cell therapies for solid tumours

May 22, 2023

The weird, the wild, and the wonderful

A discussion of some of the key topics emerging in ER+ HER2- breast cancer

May 15, 2023

Early research which points us to new cancer therapeutic opportunities

Have you ever wondered why some anti-cancer agents do well and others poorly – even with similar…

May 11, 2023

Heading to the stars in RAS driven cancers

A next generation category of KRAS inhibitors are emerging - W2W4

May 10, 2023

A cluster of new developments

What's new on the CAR-T cell therapy front?

May 5, 2023

The road less travelled

Off the beaten track can bring danger and delight in the unknown in equal measure

May 2, 2023

ASCO23 Preview 1 – W2W4 in Developmental Therapeutics

Update on Developmental Therapeutics

April 27, 2023

AACR23 Insights on gems from the poster halls – Part 1

Where we explain what to look for in 10 posters presented at AACR23

April 25, 2023

AACR23 – Is there an ADC renaissance on the horizon?

A look at some early stage ADC molecules in the clinic

April 19, 2023

AACR23 – New is not necessarily better

Orlando – At AACR23 the old adage of “be the first, or be the best” is well and truly…

April 18, 2023

AACR23 – is the Florida sun shining on KRAS?

Initial learnings on KRAS presentations at AACR23

April 17, 2023
The key to success in TPD

AACR23 Preview 8 – Keys to success in TPD

W2W4 on the TPD front

April 14, 2023

AACR23 Preview 7 – Surfeit of riches

From one compound to many competitors following in their wake!

April 4, 2023

AACR23 Preview 6 – Taking a closer look at KRAS Part 1

The ever evolving selective KRAS inhibitor & degrader space

March 29, 2023

AACR23 Preview 5 – an emerging landscape

A look at an emerging early stage oncology landscape

March 23, 2023

AACR23 Preview 4 – Stepping It Up

Continuing our evaluation and exploration of another batch of early stage anti-cancer compounds either…

March 20, 2023

AACR23 Preview 3 – Emerging agents with a different mechanism of action

As we continue our new products journey evaluating early stage agents in development with data at…

March 16, 2023

AACR23 Preview 2 – Seeing the wood from the trees

Early stage new product development part 1 - seeing the wood from the trees

March 15, 2023

AACR23 Preview 1 – What to watch for

Half a dozen key early areas to watch out for

March 13, 2023

What will novel CAR-T cells look like in the future?

In a few years time the next generation CAR-T cell therapies are going to look and behave very…

March 9, 2023

New progress in tackling intractable cancer targets

It’s all too easy to think of New Jersey as the behemoth of Pharmaland in the north east, while…

March 7, 2023

A lysing kind of winter

Improving cell therapy performance with a multitude of innovative strategies

March 7, 2023

Dark Knight Rising

Key developments which could kickstart a renaissance for CAR-T cells in solid tumours

March 2, 2023

Cool and emerging new concepts to watch out for in Gliomas

A look at some new developments in CAR-T cell therapy for gliomas

February 27, 2023

Diet as a drug

We have heard much over the last decade or so about the impact of the microbiome on responses to…

February 22, 2023

Thinking outside the Box

The next generation of CAR-T cell therapy will require out of the box thinking

February 20, 2023

Changing of the guard

How the landscape in prostate cancer could change in the medium to long term

February 17, 2023

The near term future in CAR-T cells is a’changing!

How base editing can transform the development of next gen CAR-T cell therapies

February 13, 2023

The CAR-T cell beat goes on

Some promising new early developments are coming through in AML and T-ALL - what's the skinny?

February 10, 2023

An unexpected renaissance

A rising area of interest in the CAR-T cell space

February 7, 2023

New directions in lymphomas

What will be the emerging products and regimens to watch out for in aggressive lymphomas?

January 31, 2023

Will targeting KRAS G12D prove more successful than G12C?

Going beyond the first past the post syndrome...

January 25, 2023

Cracking the code to the MYC oncogene

A novel approach to targeting an intractable oncogene

January 23, 2023

Keeping an eye on the ball in AML

An in-depth look at what's behind an upcoming milestone

January 19, 2023

Pointing the way forward

How can performance of T cell therapy be improved?

January 11, 2023

Kaizen in action

The evolving BMS-Celgene pipeline and what's coming next in new developmental twists

January 10, 2023

Shining the light

How novel bispecifics might help potentiate the impact of KRAS inhibitors when combined with checkpoint blockade

January 9, 2023

Tipping the TIGIT balance

How can we overcome immune escape in relation to TIGIT therapies?

January 9, 2023

Moving targets

Ten emerging development areas to watch out for in oncology during 2023

January 5, 2023

Chasing the alpha

A deeper look at the ARC-7 TIGIT readout

December 20, 2022

The evolution of blind spots in hematologic malignancies

A look at an evolving niche in hematologic malignancies

December 16, 2022

On the prickly issues facing the Menin inhibitors

Some key subtleties and nuances to watch out for in the Menin niche

December 13, 2022

Caveat emptor

A hard look at the KRYSTAL-7 data presented at ESMO IO

December 7, 2022

Tilting at windmills

The importance of T cell exhaustion and exploring ways to avoid it

December 5, 2022

Emerging biotechs and novel IO concepts to watch out for

10 early stage IO biotechs to watch out for

November 30, 2022

Dancing with Cancer Cells

The beat goes on for synthetic lethal approaches

November 17, 2022

A novel molecule may lead to the Secret Garden

A look at how changes in antibody design can make a potential difference

November 15, 2022

Leaves of grass

Half a dozen key posters to watch out for in early stage oncology at SITC22

November 9, 2022

Exciting new developments in the KRAS space

What started out as a short update from the recent EORTC-NCI-AACR (ENA / Triple Meeting) in Barcelona on…

November 2, 2022

The art and science of a novel immunotherapy for solid tumours

Reprogramming T cell phenotype is becoming a hot topic in solid tumours and here's why...

October 28, 2022

Targeting MYC – trick or treat?

Beyond KRAS - targeting another of the four horsemen of the apocalypse

October 25, 2022

The duality and the dark side of biomarkers

Biomarker highlights to watch out for at SITC22

October 21, 2022

On overcoming resistance to protein degraders

Are there opportunities for combining small molecule inhibitors with protein degraders?

October 19, 2022

SITC Preview 2 – a look at novel and emerging IO targets

Five areas of early stage IO developments to watch out for

October 14, 2022

SITC22 Preview 1 – Looking under the hood

6 abstracts to watch out for on how to overcome immune escape

October 12, 2022

Going beyond PARP1/2 inhibition with novel approaches

Can we overcome resistance checkpoint blockade with novel approaches to DDR?

October 7, 2022

Dawn of new directions for protein and glue degraders

Where is the TPD field likely headed with next generation approaches?

October 4, 2022

Fishing for Gems from the Poster Halls Part 1

Bispecifics come and bispecifics go as companies seek to find a balance

September 29, 2022

Reflections on ESMO22

What really stood out from the oral presentations at ESMO this year?

September 16, 2022

Analysis of the CodeBreak 200 trial in lung cancer

An in-depth look at some of the issues impacting Amgen's pivotal trial and what it means for their competitors

September 14, 2022

Sorting out confusion, confliction, and confounding results in clear cell RCC

How do we help more early stage ccRCC patients live long and prosper?

September 12, 2022

Time to change lines in breast cancer?

Round up ad discussion of key breast cancer trials in HR+/HER2- disease

September 11, 2022

Making your mind up

Are all PARP inhibitors the same?

September 10, 2022

ESMO22 Preview on Targeted Therapies in Developmental Therapeutics

New developments in early stage targeted therapy agents

September 6, 2022

ESMO22 Developmental Therapeutics Preview on Immunotherapies

In our latest ESMO conference preview it’s time to pick some early stage immunotherapy highlights…

August 31, 2022

New controversies in GI malignancies

What to watch out for in colorectal cancer, cholangiocarcinoma and hepatocellular carcinoma

August 24, 2022

ESMO22 Preview 1 – what to watch out for in breast cancer

Review of some of the key trials in breast cancer being showcased in Paris next month

August 22, 2022

New directions in small cell lung cancer

A look at promising new approaches in SCLC

August 12, 2022

Going beyond sotorasib and adagrasib

On fast followers and novel G12C combinations

August 8, 2022

The road to Damascus is paved with good intentions

Trials and tribulations associated with KRAS plus IO combos

August 8, 2022

Important new oncology developments to watch out for

6 important and encouraging new developments to watch out for

July 29, 2022

Catamaran Bio sets sail in 2022

Interview with Dr Vipin Suri, CSO Catamaran Bio about the science behind their CAR-NK cell therapy.

July 27, 2022

Are we overpromising with protein degraders?

Going beyond small molecule inhibitors to degrading various intractable targets

July 19, 2022

What do the Konami code and targeting KRAS have in common?

A rock around the KRAS clock

July 12, 2022

Shoreline rides the CAR-NK wave at AACR22

First in a mini-series featuring some of the companies that presented CAR-NK cell data at AACR22

July 7, 2022

The long and winding road to success

An emerging new and highly selective oncogenic target

June 30, 2022

An alternative perspective on TIGIT

What can we learn from IO trials in lung cancer to help us evaluate TIGIT's prospects?

June 23, 2022

Seeing the wood from the trees in early stage oncology pipelines

Exploring future IO-IO combination strategies and life cycle management

June 16, 2022

A critical review of five different targeted therapy approaches at ASCO

Where five different targeted therapies are put through their paces

June 13, 2022

The good, the bad, the plain old ugly, and the promising

There’s always a parable or two to be had at ASCO and this year was no different, especially in…

June 7, 2022

Talkin’ ’bout a Revolution

The continuous evolution of BCMA CAR-T cell therapy products and how they are doing

June 6, 2022

Trials and Tribulations

A look at early stage CAR-T cell therapies in development

June 5, 2022

ASCO22 Highlights from Day 1

When cell therapies and targeted therapies collide

June 4, 2022

Five key areas to watch out for at ASCO22

Five key areas to watch out for at ASCO22

June 1, 2022

The Forgotten Checkpoints

What can we learn from the data on inhibitory checkpoints not named PD(L)1 or TIGIT?

May 26, 2022

Up and coming cell therapy companies to watch out for

What can we learn from a raft of early cell therapy companies with novel or intriguing approaches?

May 24, 2022

A high level view of the latest Target Protein Degradation data

What's the skinny on C4 Therapeutics and other TPD programs at AACR and ASCO?

May 16, 2022

The spectre of MetMAB rises again!

Six important factors to consider when looking at the SKYSCRAPER-01 TIGIT readout

May 11, 2022

Watch to watch out for at ASCO22

Hot or not - 5 early stage trials with different agents and targets

May 5, 2022

Take the high road

5 abstracts to watch out for at the ASCO22 meeting in Chicago

May 2, 2022

A journey that never ends

Can NK cells help checkpoint blockade work more effectively?

April 27, 2022


New CAR-T cell developments in solid tumours - hit or miss?

April 24, 2022

An inconvenient truth

Looking beyond the hype from a broader perspective

April 18, 2022

Winner, winner, chicken dinner!

5 key and novel early areas of development which stood out to us at AACR22

April 11, 2022

An explosion of new opportunities in the expanding KRAS landscape

Going beyond both G12C and G12D to a plethora of new targets and combination approaches

April 10, 2022

Addressing acquired resistance through novel combination strategies

All aboard to hear more about novel targeted therapy combination strategies...

April 8, 2022

Discovering novel oncogenic targets

Finding new synthetic lethal targets to induce more potent cell death and improve outcomes

April 8, 2022

Are there challenging times ahead for KRAS inhibitor combinations?

A lion roar or whimper at the prospect of KRASi plus IO trials?

April 5, 2022

Off the beaten track in the bispecific landscape

Everything you needed to know about bispecifics at AACR22 and more!

March 31, 2022

What to watch at AACR22 on NK cells

What to watch out for at AACR22 if you're interested in NK cells

March 29, 2022

5 important topics to watch out for at AACR22 on bispecifics

5 areas to watch out for on the bispecific antibody front

March 25, 2022

The paradox of immune cell populations and transcription factors

Can you have your immune cake and eat it?

March 23, 2022

The battle for early stage lung cancer continues apace

A look at subtleties behind the PEARLS trial in adjuvant NSCLC

March 18, 2022

How – and when – should people with early stage breast cancer be treated with a PARP inhibitor?

Is the OlympiA trial groundbreaking for early stage breast cancer?

March 16, 2022

New directions and opportunities with intractable oncology targets

Just because a pathway has been called undruggable doesn't always mean it will be so!

March 15, 2022

Challenges and opportunities with two different onco modalities

The latest on bispecifics and protein degraders

March 10, 2022

AACR22 Preview 1 – Key topics to watch out for

Hot topics to follow at AACR22

March 7, 2022

Aspiring to new heights – and new modalities

Can a different twist on modality make a real difference and go beyond what we already have?

March 4, 2022

Through the keyhole look at an emerging area of drug development

Some important new research which may stimulate a whole new class of anti-cancer therapies

February 28, 2022

To degrade or inhibit, that’s the question

The battle over AR antagonists and degraders rages on as new clinical data emerge

February 23, 2022

Pulling a rabbit out of a hat

Surprises galore in the unveiling of the PARP data in 1L mCRPC!

February 21, 2022

Sotorasib impresses unexpectedly in pancreatic cancer

Trick or treat? A look at the sotorasib data in PDAC.

February 14, 2022

Olaparib drives earlier and deeper responses in mCRPC

An important phase 3 readout to mull over - what's not to like?

February 14, 2022

5 strategies for overcoming challenges to CAR-T cells in solid tumours with CAR-T cells

CAR-T cells have struggled to make an impact in solid tumours, are things changing for the better?

February 14, 2022

Is the future of CAR T cell therapy beyond Oncology?

A look at new and quite unexpected directions for CAR-T cell therapy

February 12, 2022

Novel ways to enhance CAR-T cell performance

Highlights from Day 1 CART22 Part 2

February 11, 2022

What’s the next stop in CAR T cell therapy?

Highlights from Day 1 of CART22, part 1

February 11, 2022

Challenges and opportunities with CAR-T cell therapies

Some important new papers on CAR-T cell therapies are shedding light on potential new combination strategies

February 7, 2022

Learning from what patients tumours are telling us

Cracking the tumour code

February 4, 2022

Hunting novel oncology targets

A look at an early potential oncogene target in liquid and solid tumours

February 2, 2022

Doubling down on modest data

A look at some recent phase 2 data in the KRAS niche in the context of the broader landscape

January 27, 2022

Science drives innovation

A careful look at the latest anti-TIGIT data

January 25, 2022

Finding achilles heels to tackle cancer head on

Exploring new approaches to targeting cancer

January 20, 2022

Important changes to watch out for in the GI cancer landscape

Preview of what to watch out for at ASCO GI22

January 18, 2022

Going after intractable cancer targets

It's time for an update on novel protein degraders

January 11, 2022

A different IO approach to tackling solid tumours

Can we improve the quality of T cells performance and boost outcomes?

January 12, 2022

Can C4 take protein degraders to new heights?

The intriguing science behind a novel protein degrader platform

January 10, 2022

Oncology trends and directions to watch out for in 2022

What to watch out for in 2022

January 7, 2022

A philosophical look ahead

Be more dog!

January 4, 2022

A fine line between failure and success

9 hidden Gems from the ASH21 poster hall and why you should pay attention to them

December 17, 2021

The CAR-T cell therapy merry-go-round in aggressive lymphomas

A look at a major phase 3 trial result and some of the nuances behind the data leading to a negative study

December 14, 2021

Kaizen and the art of improving CAR-T cell performance

Part 2 of our mini-series on Next Generation CAR-T cells

December 14, 2021

A new approach to overcoming CAR-T cell limitations

Overcoming the limitations associated with CAR-T performance and lack of persistence

December 12, 2021

What can we learn from early stage IO trials?

A look at some combination IO strategies in early clinical development to watch out for

December 9, 2021

Can we predict response to breast cancer therapy?

What can we learn from various breast cancer trials?

December 8, 2021

What to watch out for on the CAR-T cell therapy front

Several controversies abound in the CAR-T cell niche this year, plus what's coming next?

December 7, 2021

Going beyond the obvious in RAS driven cancers

A dozen early stage biotechs in the RAS/RAF pathway to watch out for

November 29, 2021

New developments in the cell and gene therapy landscape

Novel approaches to fine tuning CAR-T cell therapies are hitting the clinic

November 17, 2021

Lessons learned from SITC – Part 1

Sometimes we learn more from failure than we do from success

November 16, 2021

New trials and tribulations in drugging KRAS mutations

A number of new developments to consider in the KRAS niche

November 12, 2021

An immunotherapy for the long run – or tail

With SITC fast coming up this week, immunotherapies in all sorts of shapes and guises are very much…

November 8, 2021

Scores on the doors in the TIGIT niche

Update on the various runners and riders in the TIGIT niche

November 3, 2021

A review of the emerging bispecific landscape

A look at the sheer breadth and depth of bispecific approaches from a myriad of different biotechs

October 27, 2021
Washington DC in Fall

SITC21 – What to Watch out for

SITC 2021 Preview

October 22, 2021

Endless DDR changes and how we are going beyond PARP inhibitors

A detailed look at Repare's ATR inhibitor data from the TRIPLE meeting

October 15, 2021

New directions in drugging KRAS

Where next in the ever expanding KRAS runners and riders?

October 11, 2021

A look at Relay’s surgical approach to FGFR inhibition

Will Relay's FGFR2 live up to expectations?

October 8, 2021

Slicing the salami

It’s time to look at progress on the ADC front, something we sporadically cover where there are new…

October 8, 2021

Spotting the wood from the trees

What can we learn from KRASi combinations? Do any stand out?

October 7, 2021

New developments on the lymphoma horizon

Key learnings and highlights from the recent AACR DLBCL specialist meeting

October 5, 2021

When things fall apart

One of the things that struck me at this year’s ESMO conference was the sheer variety and richness…

September 29, 2021

COAST to coast – contemplating key Stage III trials in NSCLC

A deep dive into the phase 2 COAST study, along with some expert anecdotes

September 22, 2021

Spotting the path forward

Developmental Therapeutics is hard, how do companies go about finding a way forward?

September 20, 2021

No, no absolutely not!

A look at the controversial adagrasib data in mCRC at ESMO21

September 20, 2021

And the data at ESMO21 is…

A practice changing trial of note at ESMO21

September 19, 2021

Storm Clouds or Sunny Skies? What’s on the horizon for Early Stage IO Development Data at ESMO21

A hard look at some IO agents in early development at ESMO21

September 18, 2021

ESMO21 Highlights from Day 1

Key posters of interest at ESMO21

September 17, 2021

Standing out from the crowd in lung cancer

Highlights from WCLC Day 1

September 9, 2021

Novel strategies for addressing an intractable cancer target

A look at some cool science and novel strategies for tackling an intractable target

September 2, 2021

Coming back full circle

Can a genomic signature help select patients more accurately for DDR therapies?

August 26, 2021

WCLC21 Preview of key data to watch out for

What's hot at WCLC21?

August 19, 2021

Sticking it to MYC addicted cancers and other targets

It's time to tackle some intractable targets in oncology and elsewhere...

August 12, 2021

A novel target to explore in prostate cancer

Is it a marker or a target? Actually, what is the target - and why does it matter?

August 5, 2021

A bridge to a broad and deep oncology pipeline

What are Novartis up to these days with their oncology pipeline and what are they excited about?

July 29, 2021

An authentic and novel approach to designing novel anti-cancer drugs

A look at why and how Relay's early oncology pipeline might be one to reckon with

July 26, 2021

Gritting it out

What are Gritstone up to behind the scenes and where are they headed in the near-term?

July 20, 2021

Digging deep with RNA therapeutics

Can AI and deep learning help us re-program genetic defects with RNA therapies?

July 15, 2021

The interface of science, innovation, and imagination

What can deep learning techniques tell us about NASH, Parkinson's, Alzheimer's or even cancer?

July 13, 2021

New developments on the T cell engager front

Update on the T cell engager niche with an emerging agent of interest

July 8, 2021

Looking east at a now familiar horizon

A careful look at what we can learn from the Beigene anti-TIGIT data for ociperlimab

July 6, 2021

New developments in the protein degradation niche

Update on C4, Kymera, Novartis and Vividion

June 30, 2021

Tackling immunosuppression with a dual approach to TIGIT and adenosine

Do we need to target the adenosine fog as well as TIGIT in NSCLC?

June 24, 2021

Tackling a hostile tumour microenvironment on multiple fronts

Continuing our ongoing series on immunosuppression and finding ways to overcome the hostile TME

June 24, 2021

Making a difference in aggressive lymphomas

Round-up of key highlights relating to CAR-T cell therapies, CELMoDs and super-enhancer activity in DLBCL

June 22, 2021

New developments in hematologic malignancies to make your head turn

A look at two under the radar early developments in lymphomas which might have a shot at approval

June 17, 2021

Are AI and machine learning alive or dead in oncology?

How can AI and ML speed up or improve our drug discovery efforts in oncology R&D?

June 15, 2021

A look at 6 key developments in advanced hematologic malignancies

A look at 6 IO products in the Heme space and what to watch out for.

June 10, 2021

Shipping the KRAS line

Update on the Novartis SHP2 inhibitor at ASCO21

June 8, 2021

Which early phase agents look promising – or not – ASCO21?

New product development and early phase anti-cancer agents have been very much a focus on BSB (and PSB…

June 6, 2021

Unheralded developments in renal cell carcinoma

A look at what's happening in RCC and what to watch out for at ASCO this year

June 4, 2021

Is olaparib scaling new heights in OlympiA?

PARP inhibitors move into the adjuvant setting at long last? Say it ain't so!

June 3, 2021

Advent of a new era in advanced prostate cancer treatment

A look at the first anti-cancer therapy with a radiopharmaceutical in advanced prostate cancer

June 3, 2021

Dancing with proteins at the Masquerade

Who's going to the masquerade ball and how might they fare in the future?

June 1, 2021

ASCO21 Off the Beaten Track Part 2

A look at some hidden gems in the ASCO program and what it all means in terms of the science.

May 27, 2021

Off the Beaten ASCO21 Track Part 1

Hidden early stage gems to watch out for at ASCO21

May 25, 2021

Highlights and lowlights from the ASCO21 data drop

Which abstracts stood out in the initial run through of the data? Includes some hidden gems and surprises!

May 20, 2021

A twist in the IO tail

Going beyond the obvious conclusion with anti-LAG3 therapy

May 19, 2021

Digging deep on SHP2 and KRAS

New developments on the KRAS and SHP2 front

May 17, 2021

When PARP and immunotherapy worlds collide

New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.

May 12, 2021

The future of breast cancer research

Some key learnings from the ESMO Breast Cancer meeting held last week

May 10, 2021

Tooting the DDR horn

Bridging the DDR gap from AACR to ASCO

May 7, 2021

The battle of protein degraders versus inhibitors continues apace

Who's going to win in the battle between protein degraders and small molecule inhibitors?

May 4, 2021

Can a monoDAC hit the groove against IMiDs and CELMoDs?

What can we learn from C4 Therapeutics monoDAC, CFT7455?

April 28, 2021

A twist in chemical moeity

A look at the subtleties and nuances under the hood of the Arvinas PROTACs

April 27, 2021

The Future of Cell and Gene Therapies

13 ways in which CAR based or gene therapies can improve on current approaches to cell therapies

April 22, 2021

Targeting Menin and the evolving landscape for NPM1-MLLr acute leukemias

A look at new data in the Menin/MLLr inhibitor landscape in acute leukemias

April 20, 2021

Novel approaches to cell therapies – Part 1

A look at switchable CAR-T cell therapies, plus CARs based on alternative immune cells.

April 19, 2021

Highlights and commentary on key AACR21 data presentations

13 talks at AACR21 caught our attention - which ones intrigued or dismayed - and why?

April 13, 2021

AACR21 Preview 8 – The growing bispecific niche

A rock around the bispecific clock highlighting key presentations coming at the AACR 2021 virtual meeting

April 8, 2021

5 early developments to watch out for at AACR21

What's hot in early preclinical development to watch out for?

April 5, 2021

AACR21 Preview 6 Exploring a novel and early target for cancer therapeutics

A look at a potential emerging target which could be druggable

March 30, 2021

AACR21 Preview 5 Promising new developments in the PARP field and beyond

What's hot on the DDR front and PARP inhibitor space at AACR21?

March 25, 2021

AACR21 Preview 3 Novel and cool approaches emerging in oncology pipelines

Emerging areas in cool new science around targeted therapies

March 18, 2021

Novel combination strategies to enhance KRAS inhibitors

Combinations will be the future for KRAS inhibitors but which ones and why? Includes some new ideas!

March 16, 2021

The King of Kings

Capturing attention in the crowded protein degradation niche

March 11, 2021

AACR21 Preview 1 Emerging targets for protein degradation and molecular glues

What to watch out for in the protein degradation niche

March 11, 2021

The broad and deep protein degradation landscape

Getting to the centre of things with protein degradation

March 9, 2021

Using bacteria as a trojan horse to target oncogenes

Degrading oncogenic proteins with novel bacterial approaches

March 1, 2021

The potential for a novel chemotherapy approach

How prodrug technology can lead to improved delivery of potent chemotherapy in select tumour types

February 25, 2021

How innovation in chemistry can transform anticancer therapy

A novel approach to chemistry can potentially transform a therapeutic modality against cancer

February 23, 2021

La Coupe de Feu

How do we unleash more cytotoxic T cells against a cancer with a high unmet medical need?

February 18, 2021

A case to answer

Will the eganelisib data be positive in TNBC from the MARIO-3 trial?

February 17, 2021

Une Baguette Magique

What's under the hood with a personalised cancer vaccine? Quite a lot it seems!

February 12, 2021

Emerging developments and trends in advanced lung cancer

Gems from the WCLC20 poster hall which may make an impact

February 9, 2021

A look at the exon 20 landscape in lung cancer

A look at the exon 20 insertion landscape - all to play for!

February 4, 2021

What happens when genomics, KRAS, and IO converge in lung cancer?

Genomic analysis in IO trials is on the increase - what happens when PD-1 and KRAS collide?

February 2, 2021

A critical look at the Amgen sotorasib data in KRAS G12C mutated lung cancers

Discussion of the Amgen sotorasib data presented at WCLC20 in Singapore

February 1, 2021

How will AI impact oncology R&D?

Some intriguing convergence from two recent conferences offers new insights from an AI perspective

January 28, 2021

Old Dog New Tricks

Exploring a novel approach to overcoming immunotherapy resistance

January 26, 2021

Lessons learned from phase 1 oncology trials

A novel IO target with a chequered history is starting to look more promising - which one and why?

January 21, 2021

Parallel lines: opportunities and challenges in GI cancers

Important developments on the GI cancer front to watch out for

January 19, 2021

Strategic direction and future impacts in multiple myeloma

A rock around the myeloma clock through the eyes of a KOL - what stood out and what did not?

January 14, 2021

How bispecifics will make an impact in myeloma

Beyond CAR-T cell therapy there are novel bispecifics coming along so where and how will they fit in?

January 13, 2021

Looking through the window at the cilta-cel data

A look at what we can learn from the cilta-cel BCMA CAR-T cell therapy data and where things are likely headed

January 12, 2021

An exciting pipeline of early stage oncology agents from BMS

A critical look at the early stage BMS oncology pipeline

January 11, 2021

Future of NK Cell Therapy – Part 2

Commentary on engineered NK cells, including CAR-NK and memory-like NK cells

January 6, 2021

Future of NK Cell Therapy – Part 1

Expert commentary on new data relating to NK cell therapies - are they ready for prime time yet or not?

January 5, 2021

Important learnings from targeted therapies from SABCS

What's worth following on the targeted therapy front in breast cancer? A look pipelines and new indications from SABCS

December 17, 2020

Finding success in hard to treat breast cancers

Post SABCS analysis of a key topic and cancer driver

December 15, 2020

If it’s Tuesday it must be Belgium

It's time to turn our attention to novel TKI approaches in hematologic malignancies

December 8, 2020

A critical review of bispecific antibodies at ASH20

What caught our attention on novel bispecific antibodies at ASH20?

December 7, 2020

ASH Day 1 highlights and lowlights Part 2

Highlights on translational research and clinical trials in AML and BCLA CAR T cell therapy

December 6, 2020

Highlights of Saturday at ASH20 Part 1

Commentary on Saturday at ASH20

December 6, 2020

Bigging up targeted therapies at ASH 2020

W2W4 in targeted therapies at ASH20 - some key early stage areas to focus on

December 4, 2020

ASH20 Preview – Part 1 on small molecule developments

New developments in the BTK niche offer fresh insights on progress

December 1, 2020

ASH20 CAR-T cell therapy Preview

Rock around the CAR-T cell clock to learn what to watch out for at ASH20!

November 24, 2020

When IO, targeted therapy and oncogene worlds collide

Oncogenes and tumour suppressors can have surprising effects on targeted therapies and immunotherapies

November 20, 2020

Hot Topics: What we learned from SITC20 about an emerging class of oncology agents

A look at several different innate immune system approaches

November 18, 2020

ASH20 Preview 2 on Antibodies and ADCs

What's hot on the antibody and ADC front at ASH 2020?

November 12, 2020

ASH20 Preview of progress with bispecific antibodies

Updated look at the bispecific landscape in early clinical development

November 9, 2020

Notes from a small island

new approaches to applying translational research to the clinic in oncology R&D

November 3, 2020

Moving On Up

We still need to kill cancer cells to get durable complete responses - a look at ways to accomplish this feat

October 29, 2020

Buildings walls versus building cathedrals

The devil is in the finer details...

October 27, 2020

What can we learn from Mirati’s adagrasib in lung and other cancers?

It’s time to look at the latest update on KRAS mutation specific agents in clinical development as…

October 25, 2020

TRIPLE highlights and lowlights in Developmental Therapeutics

The trials and tribulations of targeted agents in developmental therapeutics

October 25, 2020

On finding new targets and boosting existing therapies

Science drives oncology new product development and the AACR special conferences are always a good place…

October 22, 2020

Potential new targets and biomarkers for immunotherapy

How we can learn more from failure in clinical trials so we can improve outcomes further with emerging agents in early development

October 20, 2020

New developments in the KRAS landscape

An update on two very different targets in the broader KRAS niche, one of which may have a particularly long lasting impact on the landscape.

October 15, 2020

New ways of thinking about the immune landscape

How early evolutionary changes in cancer can impact hot/cold regions and patient outcomes

October 13, 2020

A contrarian view of key cancer trial results

Winners, losers and risers... who goes where in the final analysis?

October 8, 2020
Hubble Space Telescope, Spitzer Space Telescope

On black holes and rising supernova stars in oncology

Rising stars become supernovas or disappear into a black hole of R&D - a look at what we can learn from one company's early stage compounds

October 6, 2020

Marseille Immunopôle PIONeeR Project provides insights at ESMO20 into Lung Cancer Immunotherapy

Commentary on data presented at ESMO20 for PIONeeR Lung Cancer Immunotherapy Project

October 1, 2020

A phoenix rises from the ashes

A look at one oncology biotech company's early pipeline and how it fits in with the emerging landscape

September 23, 2020

Important learnings from ESMO20

Surprising new developments in early stage breast and metastatic prostate cancers

September 21, 2020
Flashing Red Light on Level Crossing

ESMO20 Un train peut en cacher un autre

Reflections on data in early breast cancer and NSCLC presented on Sunday at #ESMO20

September 21, 2020

Highlights of Super Saturday at ESMO20

Solid tumour highlights from ESMO not including breast cancer

September 20, 2020
TDF London 2014

Why Saturday at ESMO20 is like the Tour de France

Breast cancer highlights from Saturday at ESMO20

September 20, 2020

Highlights from Mini Oral Sessions at ESMO20

Commentary on Day 1 at ESMO20 and data presented in the mini oral sessions

September 19, 2020

ESMO20 Preview 4 – Targeted therapies to watch out for

What to watch out for this weekend in targeted therapies and early stage new product development

September 17, 2020

ESMO20 Preview 3 Developmental Therapeutics – IO therapies

Five IO areas in early stage development to watch out for at ESMO20

September 15, 2020

ESMO20 Preview 2 – New Targets, New Opportunities

Can we predict the future cancer drug combinations from emerging new targets?

September 10, 2020

ESMO20 Preview 1 – Key progress in biomarker development

A look at progress and new developments in cancer biomarker developments

September 9, 2020

Encouraging progress in immunometabolism

Novel approaches to metabolism may have far-reaching effects on anti-cancer therapies

September 1, 2020

A novel approach to enhance adoptive cell therapy

Using CRISPR screens to find new targets for enhancing T cell fitness

August 25, 2020

Pillars of future strategies in tackling aggressive lymphomas

Some intriguing new developments in DLBCL to watch out for

August 20, 2020

Potential of Immunometabolism to Enhance CAR T cell therapy

How can we use metabolic reprogramming to enhance CAR T cell therapy?

August 18, 2020

A novel way to target KRAS mutant lung cancer

Rare mutations in lung cancer (STK11/KEAP1) could be associated with defects in cancer metabolism - we look how they impact KRAS mutant lung cancer

August 13, 2020

Targeting Glutamine for Cancer Immunometabolism

Can we influence T cell fitness and performance by manipulating metabolic processes?

August 11, 2020

Building up a storm against resistant solid tumours

Today’s focus is on an emerging new biotech company with potential to make an impact in difficult to…

August 5, 2020

Looking for Signals in Cancer Immunometabolism

In this post we’re taking a look at what we learnt about immunometabolism at AACR20 and some of the early signals from a cancer new product development perspective.

August 6, 2020

A Journey into Immunometabolism and its Potential for Cancer Immunotherapy

The aim of this post is to give you a sense of the potential of immunometabolism to impact T cell fate, fitness, and function.

August 4, 2020

Controversial developments in pancreatic cancer

What can we understand from novel research on the biology of the disease that might lead us to new cancer therapeutics?

July 30, 2020

What’s the skinny on a new IO target in oncology R&D?

A new emerging IO target of interest caught out attention, now what?

July 28, 2020

A new dawn for epigenetic therapy in oncology

A novel epigenetic target may have far-reaching outcomes for cancer patients

July 23, 2020

The magic of making proteins disappear

A look at Kymera's protein degrader pipeline

July 21, 2020

An interesting turn of events for GSK and the BCMA niche

Was the ODAC hearing a win or loss in the GSK vs FDA battle for the first BCMA approval?

July 14, 2020

The brightest flame casts the darkest shadow

George Martin’s quote seems rather apt this morning as NextCure announced there was disappointing…

July 13, 2020

Making a splash in the competitive CAR-T space

If we were to tackle CAR T cell therapy design differently, how would we go about doing it?

July 13, 2020

New developments in CAR-T cell therapies including controversial ones

The ups and downs of CAR-T cell therapy development continues apace

July 8, 2020

Putting NK cells to work

Can we make NK cells work harder with gene editing? It looks as though this will be a feasible strategy to pursue...

July 7, 2020

Are gamma delta T cells ready yet for prime time?

Update on the Gamma Delta T cell niche - what's new, what's up, and what's down?

July 1, 2020

Will a novel way to target IL–18 be a winner?

Will we have more success targeting IL-18 to boost anti-tumour immunoty than other cytokines?

June 29, 2020

Looking through the window at some novel new product development concepts in oncology

A look at some novel and promising approaches in early oncology new product development

June 24, 2020

How the immune response to cancer can be shaped by the nature of the cancer cells

Looking under the hood in NSCLC at underlying mutations and whether or not they impact survival

June 23, 2020

Reflections on the latest lurbinectedin and abemaciclib developments

What can we learn from the recent announcements for lurbinectedin in 2L SCLC and the CDK4/6 inhibitors in adjuvant HR+HER2- early breast cancer.

June 17, 2020

Who is winning the CD20xCD3 Bispecific Race to Market?

An update on the CD20 x CD3 bispecific with expert commentary on data at ASCO EHA.

June 15, 2020

Important findings on the renal cell cancer front

There's a wealth of clinical and biomarker data to explore in RCC, which may have implications for prescribing changes in the near future

June 12, 2020

Solid tumour winners and losers at ASCO20

Highlights from several solid tumour trials in both early and late stage disease.

June 9, 2020

Hematology Winners and Losers at ASCO20

Which hematology products in development produced the best data at ASCO 2020? We took a look at the key studies in lymphomas and myelomas to find out.

June 4, 2020

A rock around the breast cancer clock

Highlights from various breast cancer trials and new pipeline developments

June 2, 2020

Can we add fire to the immune system with TIGIT?

A look at Genentech's tiragolumab (anti-TIGIT) in advanced lung cancer

June 1, 2020

A false dawn in adjuvant EGFR mutant lung cancer? Dr Ross Camidge provides a critical review of ADAURA

Dr Ross Camidge provides a critical review of ADAURA trial of osimertinib in adjuvant EGFR mutant lung cancer presented at the 2020 ASCO annual meeting.

June 1, 2020

Reflections on bench to bedside progress

From bench to bedside has many twists and turns along the way - an update on a longitudinal story we have been following for 5 years

May 29, 2020
Gems from the ASCO Poster Halls

What to watch out for in Developmental Therapeutics at ASCO20

10 developmental therapeutics abstracts to watch out for at the ASCO 2020 virtual meeting

May 28, 2020

What’s new in advanced breast cancer?

There are a few new developments of note to consider from ESMO Breast this weekend plus more to come at ASCO20 on Friday

May 26, 2020

Will the next generation SERDs make an impact in ER+ HER2- breast cancer?

An in-depth look at the emerging SERD landscape in ER+ metastatic breast cancer

May 21, 2020

ASCO20 Preview on the importance of modality in oncology R&D

Does modality matter in oncology drug development and if so, where?

May 19, 2020

Engineering Immunity – what did we learn from ASGCT20?

There are some creative and innovative new CAR T cell therapy designs being developed - what are they and where will they be tested?

May 14, 2020

ASGCT20 Gems from the ePoster Hall

Review of 12 posters that caught our attention in the ePoster Hall at ASGCT20

May 14, 2020

Highlighting an under-rated clinical development at ASCO20

Another fine example of how our understanding of the biology underpinning a certain type of cancer can lead to drugging the undruggable (no, it's not KRAS!)

May 14, 2020

Is the Arvinas PROTAC Proof of the Pudding?

What do we learn from the initial data with novel PROTAC technology?

May 13, 2020

The Potential of CAR-NK Cells for Cancer Immunotherapy

Will CAR-NK cells follow CAR-T cell therapies and hit prime time?

May 13, 2020

Putting some colour on the TIGIT niche

A look at what a young up and coming biotech in the TIGIT space are doing and how they see their approach being differentiated from the competition.

May 12, 2020

New directions in adenosine axis targeting

A raft of updates on the R&D pipelines in the adenosine niche, plus a biotech company interview

May 7, 2020

Flying high in the DDR oncology niche

New developments in the DDR niche suggest a whole new approach to tackling solid tumours beyond women's cancers, pancreatic and prostate cancer might be feasible.

May 5, 2020

Novel anti-cancer agents to watch out for

A look at five novel anti-cancer agents in early R&D pipelines and what we can learn from their experiences

April 30, 2020

Standing out from the crowd

One particular presentation stood out from the others at AACR20 this year

April 29, 2020

Postcard 2 on Adoptive Cell Therapies from the AACR20 Virtual Meeting

In our latest postcard from AACR20 virtual meeting we take a look at the adoptive cell therapy plenary session

April 28, 2020

Postcards from Day 1 of AACR20

Commentary on Day 1 of the AACR20 Virtual Meeting

April 28, 2020

One swallow does not a summer make

Why you should be wary of the hype surrounding the Iovance TIL data in NSCLC at AACR20

April 27, 2020

AACR20 – Ten New Directions in Early Cancer Drug Development

Ten intriguing novel agents in early development to watch out for

April 23, 2020

Reflections on new developments in the KRAS niche

Beyond KRAS G12C inhibitors, there are plenty of other related targets to consider including KRAS::SOS1 and SHP2

April 20, 2020

AACR Preview 2 – Pathways to Success in Targeted Therapies

A look at a wide array of targets, modalities, new agents and companies through the lens of targeted therapies

April 16, 2020

Every cloud has a silver lining

What to watch out for at AACR20 - the first of our meeting previews is here!

April 15, 2020

Impact of Covid–19 on Cancer Conferences

A look at the revised schedule and timelines for upcoming Spring cancer conference season

April 13, 2020

Time is ticking on the bromodomain landscape

Where are they now four years on? A look at the BET/Bromodomain landscape

April 3, 2020

Exploring the immunological links between lung cancer and Covid–19

Some immune cells overlap in cancer and Covid-19 so what can we learn from them in order to make an impact?

March 31, 2020

Alternative cell therapy approaches to tackling cancer

How can we go about improving cell therapy approaches?

March 26, 2020

Unlocking novel IO targets and anti-cancer agents in early development

When T cells stop working how can we get innate immune cells like NK cells to take up the slack and help track down tumours?

March 24, 2020

Novel Targets and Agents – Part 2

In the first part of the review on novel targets in hematologic malignancies, we covered five key areas…

March 20, 2020

How to tackle immune suppression in multiple myeloma

Tackling immune suppression in hematologic malignancies may improve outcomes with existing regimens

March 18, 2020

The next wave of IO agents for combination therapies

Reprogramming the tumour microenvironment - can it be done and if so, how and what should be targeted?

March 12, 2020

When everyone zigs, zag

Can we learn from what a patient's tumour is telling us in terms of what the immune system is responding to in order to target it therapeutically?

March 10, 2020

A core strategy or trick play in cancer research?

Manipulating immune cells in order to harness great antitumour responses to immunotherapy

March 5, 2020

When oncology and coronavirus worlds collide

Key RNA transcription factors may have a role to play as therapeutic targets for both cancer treatment and the coronavirus

March 4, 2020

Under the Radar

An expert interview with a leading immunologist who discusses two translational opportunities with potential for cancer immunotherapy

February 28, 2020

A look at Mirati in the context of the broader KRAS niche

An interview with Mirati's Chuck Baum and Jamie Christensen exploring the evolving opportunities and challenges in the KRAS G12C niche

February 25, 2020

Overcoming challenges associated with cell therapy approaches

Insights from Transplantation & Cellular Therapy (TCT) meeting on the next generation of CAR T cells

February 21, 2020

A hidden gem in the KRAS niche

Monotherapy approaches won't be enough to shut down KRAS mutations in solid tumours, so what targets can we add in to reduce acquired resistance?

February 19, 2020

New developments in Genitourinary cancers

Highlights from ASCO GU 2020 with some interesting targets and emerging molecules to consider

February 17, 2020

Whipping up a frenzy in CAR-T cell future developments

In this post we look at an emerging research area that will be important to address if CAR T cell therapy is to be effective in solid tumours

February 13, 2020

Quest for the Holy Grail of Cell Therapy

CAR T cell therapy for solid tumors is the cancer new product development equivalent of the quest for the "Holy Grail."

February 11, 2020

What does the next decade hold for CAR T cell therapy?

Interview with Dr Carl June on what the next decade holds for CAR T cells, cell therapy and genome engineering

February 6, 2020

A delicate question of balance

Interview with Prof John Gribben at second European EHA EBMT CAR T cell therapy meeting in Sitges, Spain

February 5, 2020
Sitges Sunrise

Chasing the Light in Cell Therapy

Commentary on Day 2 of the EHA EBMT 2nd European CAR T cell meeting

February 1, 2020

Shooting for the stars with next generation cell therapies

Commentary on first day of EHA EBMT European CAR T meeting in Sitges, Spain

January 31, 2020

Life, the world, and the cell therapy universe

Can innovative our ability to reinvigorate stalled CAR T cells affected by immune escape from CD19 loss or downregulation of BCMA?

January 30, 2020

An up and coming IO company to watch out for

Looking beyond CAR-T cells and checkpoint blockade, there are some promising young companies on the rise to watch out for - here's one of them

January 29, 2020

New developments in GI cancers from ASCO GI 2020

A report card on important trial updates across gastric, pancreatic, liver, and colorectal cancers at ASCO GI 2020.

January 27, 2020

Lining up multiple approaches in AML

Novel approaches in AML seek to overcome the challenges of the past and improve clinical outcomes.

January 23, 2020

Competition rapidly heats up in the KRAS space!

Overcoming acquired resistance to KRAS inhibitors will be key to success - here's one potential way to do that.

January 20, 2020

Will 2020 be an inflection year for Kura Oncology?

Update on Kura Oncology's progress with tipifarnib and their emerging pipeline

January 16, 2020

JPM20 Highlights from Day 3

What's in store on the penultimate day of JPM20?

January 15, 2020

JPM20 Highlights from Day 2

Highlights (and lowlights) from the second day of the JPM Healthcare conference in San Francisco

January 14, 2020

JPM20 Highlights from Day 1

Highlights and lowlights from Day 1 of JPM20

January 13, 2020

Lining up new developments in the treatment of GVHD

Following the recent failure of Incyte's itacitinib in acute GVHD, we look at promising early developments following in their wake.

January 13, 2020

The Evolving Competitive Landscape for TIM-3

TIM-3 may have a role to play in myeloid hematologic malignancies such as AML and MDS. We explore the scientific rationale, competitive landscape, and initial clinical data.

January 8, 2020

The Future of Oncology R&D

Six key strategic factors to consider going forward in the quest for future oncology R&D pipelines

January 6, 2020

Novel agents and targets – Part 1

Some novel targets, new agents and some twists in the tale to consider in hematologic malignancies

December 19, 2019

The dog that didn’t bark

A look at what happened from the DREAMM1 to DREAMM2 trials exploring the BCMA ADC belantamab mafadotin in refractory multiple myeloma and why GSK have a challenge ahead

December 17, 2019

Is pembrolizumab superior to atezolizumab in neoadjuvant TNBC?

A look at the KEYNOTE-522 and neoTRIP clinical trials in neoadjuvant TNBC

December 12, 2019

Highlights and lowlights in HER2+ metastatic breast cancer at SABCS19

A look at tucatinib, margetuximab and trastuzumab deruxtecan in HER2+ advanced MBC

December 11, 2019

In Plain Sight

A look at some of the highly ranked clinical data presented over the weekend in Orlando

December 9, 2019

Friday Scientific Workshops are the Perfect Warm-Up act to ASH19

Science Friday at ASH19 with a look at various lymphoma and myeloma developments

December 7, 2019

Update on the KRAS Runners and Riders

A look at new developments in the KRAS niche and also a potential emerging novel target in addressing the development of acquired resistance.

December 3, 2019

10 early phase ASH19 abstracts with a difference

A look at off Broadway abstracts on early new product development and scientific findings of interest

November 26, 2019

9 up and coming non-T cell based immunotherapy approaches

Non-T cell based immunotherapies that could be promising in hematologic malignancies

November 21, 2019

ASH19 10 innovative approaches in Hematologic Malignancies

Some hidden gems and under the radar abstracts that may appeal to the off-Broadway crowd at ASH19

November 19, 2019

Highlights from small biotechs at SITC 2019

Highlights from SITC 2019 including small cap biotechs with novel or innovative approaches to consider

November 12, 2019

The Best Clinical Data at SITC wasn’t NextCure’s NC318 Siglec–15

Analysis and commentary of Nektar's IL-2 cytokine bempeg in combination with nivolumab in 1L advanced melanoma

November 11, 2019
National Harbor Maryland

Key Highlights from Day 1 at SITC19

If we want to improve on the current results with IO therapies then we need to go to basics and understand the biology of each disease subset in the context of what we've learned so far

November 8, 2019

New developments in targeting the B cell receptor pathway

It's time for an update on new participants to the runners and riders in CLL and NHL. Some interesting findings with BTK inhibitors to consider here!

November 7, 2019

SITC19 Preview: Which new IO data that grabbed our interest?

What's hot at SITC19 this year? We highlight half a dozen key presentations of interest to BSB readers and explain why they matter.

November 5, 2019

The potential of innovative mouse models to recapitulate the microbiome of cancer patients

What new things will we learn about the microbiome at SITC19?

November 4, 2019

Insights on targeting the oncogene SHP2

How do we improve responses to EGFR, BRAF & KRAS inhibitors? One way may be add in a SHP2 inhibitor - we look at why this target matters and which competitors are in this niche.

October 30, 2019

New path to market opportunity for Kura in SCCHN

KRAS isn't the only RAS mutation seeing progress - there's also HRAS which is now druggable thanks to Kura Oncology's tipifarnib

October 29, 2019

What do we learn from a first look at Mirati’s KRAS G12C inhibitor MRTX849?

Dr Pasi Janne presented the initial first-in-man data from Mirati's KRAS G12C inhibitor MRTX849 - what did we learn?

October 28, 2019

Targeting NRG1 Gene Fusions

What did we learn at #Targets19 about targeting NRG1 gene fusions with MCLA-128?

October 27, 2019

Further issues surrounding RAS inhibition in oncology

On dosing issues, read across from BRAF in CRC, what is SOS1 and a look at future combinations...

October 25, 2019

A novel approach to targeting BRAF and KRAS mutant cancers

How do we go about targeting KRAS mutations beyond G12C? Here's one elegant way that is promising yet very early in which it could be approached...

October 23, 2019

Eyes on CAR-T Cell Therapy in Europe – Future Directions

There are some potential unexpected new pretenders to the Novartis and Kite's CAR-T cell therapies in Europe. We discuss what they are and why they should be taken seriously.

October 17, 2019

Insights from KEYNOTE-522 in early stage TNBC

As checkpoint therapies start moving into early stage disease, how do we go about deciding which people to treat? An example using TNBC.

October 15, 2019

New directions in HR-positive breast cancer

Where are CDK4/6 inhibitors going and are there new opportunities for this class of agents outside of HR+/HER2- breast cancer?

October 14, 2019

PARP inhibition in metastatic prostate cancer

What can we learn from the phase 2 trials with PARP inhibitors in mCRPC? Quite a lot, it would seem...

October 9, 2019

Crossing the Rubicon

Insights from a US KOL on the phase 3 PROfound trial exploring olaparib in mCRPC

October 8, 2019

ESMO19 Day 4 Highlights including the PROfound trial in advanced prostate cancer

Highlights from the PROfound trial in advanced prostate cancer and other stories of interest

September 30, 2019

ESMO19 Day 3 Highlights and Commentary

Key findings and commentary on the third day of ESMO

September 29, 2019

Insights on osimertinib in 1L NSCLC from the lens of the FLAURA trial

A look at the FLAURA overall survival results and what we can learn from the phase 3 trial

September 28, 2019

Update on Amgen’s KRAS inhibitor in solid tumours

We saw signs of activity from Amgen's KRAS G12C inhibitor in lung cancer at WCLC so it's time to look at what happens in colorectal cancer.

September 28, 2019

ESMO19 Highlights from Day 2

Review and analysis of key trials presented on the second day at ESMO 2019

September 28, 2019

ESMO19 Highlights from Day 1

Commentary and Insights from Day 1 of ESMO19

September 27, 2019

ESMO19 Preview 3 – Tackling immune suppression

Some early stage oncology agents in development that seek to target and tackle inhibitory and immunosuppressive factors

September 23, 2019

ESMO19 Preview 2 – Targeting Synthetic Lethality and Immune Response in GU malignancies

Preview of ESMO19 around targeting DNA damage repair (DDR) for GU cancers.

September 18, 2019

Controversies in triple negative breast cancer at ESMO19

What should we be watching out for in terms of red and green flags at ESMO on the breast cancer IO front?

September 16, 2019

The many faces of lung cancer

WCLC 2019 Review – Part 3 - Targeted Therapy Highlights excluding KRASi

September 12, 2019

New developments in immunotherapy from WCLC19

Summary of IO highlights and lowlights from WCLC 2019

September 10, 2019

Targeting KRAS – Highlights from WCLC 2019

Barcelona – Gosh, what a weekend chock full of lung cancer data at the World Congress on Lung Cancer…

September 9, 2019

Overcoming a hostile tumor microenvironment with Siglec-15

Is Siglec-15 a key target in overcoming immunosuppression in some cancer patients?

September 6, 2019

Targeting Siglecs for Cancer Immunotherapy

An initial primer on the emerging area of Siglecs within the glycobiology niche

September 5, 2019

Will bromodomain inhibitors and PROTACs make an impact?

A look at BET-bromodomain inhibitors, PROTACs, stapled proteins and more on MYC

September 4, 2019

Can a new class of agents therapeutically target the MYC or RAS oncogenes?

How do we go about therapeutically targeting deep protein-protein interactions that can cause aberrant cancer activity? Here's one novel approach in early development...

September 3, 2019

Gerard Evan discusses inflammation and immune suppression in cancer

How do mission critical oncogenes cooperate and act in concert in cancer?

August 30, 2019

Why does Myc drive out T cells?

If we want to be able to drug oncogenes such as MYC then we need to figure out how they work and function to find the achilles heel

August 29, 2019

On the interaction between transcription factors and the immune system

A potential role for epigenetic therapies in straddling the divide between transcription factors and the immune system...

August 26, 2019

Through the window on the MYC oncogene

What can we learn about the MYC transcription factor and oncogene in order to turn it into a viable target in oncology R&D?

August 21, 2019

Novel DDR combinations and regimens that could make a difference

Latest preclinical and clinical news and readouts as well as forthcoming trial presentations to look forward to in the DDR space

August 16, 2019

A STING in the long tail?

What can we learn from recent trial data exploring a STING agonist in combination with anti-PD-1 in advanced solid tumors including TNBC & melanoma?

August 2, 2019
Lightning bolt

Is the BMS CheckMate-227 trial a hit or miss in lung cancer?

Our latest analysis of the ever evolving NSCLC landscape following BMS’s announcement on CheckMate-227

July 25, 2019

Insights on the Jounce-Celgene collaboration and ICOS agonism

Thoughts and commentary on the Jounce-Celgene collaboration update and the emerging ICOS landscape

July 24, 2019

New developments in Sarcoma

A review of our Top 10 sarcoma results from ASCO19 plus commentary from a specialist KOL in this niche

July 23, 2019

A look at Amgen’s early oncology pipeline

Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?

July 18, 2019
Cambridge from Bay Bay Boston

An in-depth look at Neon’s updated neoantigen vaccine data

Insights on the updated phase 1b clinical data evaluating Neon's personalized vaccine NEO-PV-01 in combination with nivolumab in advanced cancers?

July 17, 2019

Will innate bispecifics make a difference in hematologic malignancies and solid tumours?

What can we learn from the recent data presented on Affimed's innate bispecific platform? A candid conversation with CEO, Dr Adi Hoess

July 11, 2019

How F-star are optimising bispecific antibodies for cancer treatment

Next generation IO molecules are likely to feature bispecific antibodies - can we address the weaknesses seen with immune agonist antibodies by switching modalities?

July 10, 2019

The Next Wave of IO with Dr Dan Chen

We saw a number of challenges emerge with immune agonists as antibodies and now companies are experimenting with them in bispecifics - what needs to be considered to make them work? What will the next wave of IO look like?

July 9, 2019

mRNA – the language of life

Can mRNA disrupt cancer therapy and boost responses beyond what we see with checkpoint therapy?

July 3, 2019

Dracarys! How T cell therapy is like Game of Thrones

Is T cell therapy like Game of Thrones?

July 1, 2019

Waves and waves of T cells

What can we learn from biomarkers and immune profiling in patients receiving bempeg, a CD122-directed pegylated IL-2 therapy

June 27, 2019

Navigating new opportunities in the IL-2 space

How is Synthorx's IL-2 cytokine THOR-707 different from other compounds in this niche?

June 26, 2019

How failure allows us to continually innovate

How the design of different cancer approaches can affect clinical performance

June 24, 2019

Key highlights on lymphomas from iCML

Round-up and analysis of key lymphoma data at iCML 2019

June 20, 2019

Alternative approaches to targeting cytokines

Can we employ red blood cells in allogeneic, off-the-shelf cellular therapy products for the treatment of cancer?

June 19, 2019

The value of biomarkers in rescuing oncology R&D

Update on PTCL developments and a possible new therapy that may be approved in this setting

June 14, 2019

What’s new with Corvus Pharma?

New data suggests there may be value in targeting CD73 as well as the A2A receptor in certain tumour types...

June 11, 2019

How understanding patient tumours can help us with future IO trials

Looking under the hood to find biomarkers of response and outcomes, ,

June 10, 2019

Did the SOPHIA data set the house on fire?

Thoughts on Macrogenics phase 3 SOPHIA trial exploring margetuximab vs. trastuzumab - hit or miss?

June 4, 2019

Manic Monday at ASCO19!

On KRAS in lung cancer, HRD in pancreatic cancer (not POLO) and genomics in RCC

June 4, 2019

Highlights from Plenary Sunday at ASCO19

A look at some of the hidden gems and struggling compounds in competitive niches at ASCO19

June 3, 2019

Highlights of Day 2 at ASCO19

Insights from Day 2 of ASCO19, plus a look at what to expect in the plenary and other sessions today.

June 2, 2019

Highlights of Day 1 of ASCO19

A review of some this key data presented including new compounds in early development and how they stack up against existing therapies.

June 1, 2019

Ten Underrated ASCO19 abstracts

Hidden gems - what to watch out for at ASCO19 off the beaten track amongst the wealth of data to peruse

May 30, 2019

What to watch out for in Bispecifics at ASCO19

A review of 7 different targets and 18 different compounds in the maturing and highly competitive bispecific niche.

May 28, 2019

Insights from CIMT in Mainz Part 2

Highlights (and lowlights) from Day 2 of immunotherapy presentations at CIMT 2019 in Mainz.

May 23, 2019

Insights from CIMT in Mainz Part 1

A report from the CIMT 2019 annual meeting exploring key highlights from the presentations on tumour biology and cancer immunotherapy.

May 21, 2019

Where’s the next exciting IO target coming from?

Working out which are markers versus valid targets is going to be key in IO progress. Here we look at one particular candidate...

May 20, 2019

Challenges of targeting KRAS G12C and why Amgen’s AMG 510 may not be a winner

Exploring the many challenges associated with targeting KRASG12C and why we should temper enthusiasm for this niche

May 15, 2019

Can Silverback increase the Firepower of TLR agonists?

A review of the latest available TLR data and a look at an emerging biotech Silverback Therapeutics in this niche

May 9, 2019

Dancing with proteins

Proteins change shape, both temporally and also in response to different conditions. Can we use this information to develop novel cancer therapeutics? One company is exploring ways of achieving this.

May 6, 2019

There is a deeper world than this

A look at inducing apoptosis of cancer cells via CDK7 inhibition and the future for rational combo approaches.

May 1, 2019

Going back to basics

How next generation immunotoxin approaches can overcome capillary leak syndrome and be effective anti-cancer agents

April 29, 2019

Chipping away at cancer

Gritstone have evolved from start-up biotech to clinical stage oncology company. We catch up with them and discuss their latest progress.

April 25, 2019

Incysus Targets GBM with Gamma Delta T Cells

Can gamma delta T cells be effective as a therapeutic in GBM?

April 23, 2019

Going beyond BCMA as a target in multiple myeloma

Is there a better way to target myeloma than with BCMA alone? Data suggests there's plenty of room for improvement.

April 22, 2019

Targeting the adenosine pathway in cancer immunotherapy

A look a the updated adenosine pathway landscape and how it is progressing

April 18, 2019

Are 𝞬𝝳 T cells immuno-suppressive and should we delete them?

As look at ways of targeting 𝞬𝝳 T cells, we may need to consider whether or not the situation is immunosuppressive or proliferative

April 17, 2019

Targeting neutrophils for cancer immunotherapy

Neutrophils may be responsible for inducing immunosuppression and resistance to checkpoint therapies so how do we target them in the clinic?

April 15, 2019

Going beyond PARP inhibitors to improve cancer outcomes

We've heard much about PARP inhibitors but they aren't the only targets in DDR we can hit...

April 11, 2019

The Future of Cancer Immunotherapy Biomarkers

With the help of a leading pathologist, we examine the challenges associated with PD-L1 and TMB as biomarkers for patient selection

April 9, 2019

How confident can we be in the reproducibility of the IMpassion130 results in TNBC?

Having a companion diagnostic is important for precision medicine, but can they accurately predict who is most likely to respond to cancer immunotherapy?

April 8, 2019

The Wisdom of Crowds

Mobbed posters indicate attendee interest, but is it justified?

April 3, 2019

Is the Apexigen anti-CD40 data hit or miss?

A look at Apexigen's anti-CD40 data in advanced pancreatic cancer - hit or miss?

April 2, 2019

Five early emerging trends to note from AACR19

What are the emerging trends from AACR19? What can we expect to see emerge over the next year?

April 1, 2019

10 things innovators should know about novel cancer targets at AACR19

Preview of AACR19 in Atlanta and what you need to know about ten novel cancer targets with data at the meeting.

March 25, 2019

AACR19 Preview of Cancer Immunotherapy Sessions – Part 2

In the second part of our review of the AACR19 cancer immunotherapy program, we take a look at more noteworthy sessions in Atlanta.

March 21, 2019

AACR19 Preview of Cancer Immunotherapy Sessions – Part 1

First part of a look at the immune-oncology track at AACR19 - there's a LOT going on this year!

March 20, 2019

Could targeting Regulatory T cells be a game changer?

Do we need to target Tregs in order to get more anti-cancer efficacy with immunotherapy? We take a look at what we've learnt about this niche.

March 18, 2019

Where are the next Immuno-Oncology breakthroughs coming from?

In order to generate more IO therapies, we first need to get a better grip on the underlying biology.

March 13, 2019

Defense is the Best Attack – Part 1

Update on T cell bispecifics and other key topics in early stage IO development

March 12, 2019

A tale of 3 cellular therapy companies

A snapshot of 3 UK cell therapy companies, Autolus, Achilles and GammaDelta Therapeutics

March 11, 2019

Sailing into the IO headwind

Figuring out how to combine different IO approaches will take time so what have we learned lately?

March 7, 2019

Sorting signals from the noise

PARP plus IO and IO combos are becoming all the rage, what can we learn from early signals?

March 5, 2019
TC BioPharm Office Building

TC BioPharm leads the way in allogeneic gamma delta T cells

TC BioPharm are a cell therapy company to watch out for as they look towards an IPO in 2020

March 4, 2019

Gamma delta T cell cancer immunotherapy in China

What can we learn about gamma delta T cell cancer immunotherapy in China?

February 28, 2019
Aerial View Thames Estuary

Emerging Gamma Delta T Cell Cancer Immunotherapy Landscape

A look at the γδ T cell competitive landscape with cell therapies, antibodies and bispecifics in early stage development

February 27, 2019

Are gamma delta T cells the next wave of cell therapies?

Can we make novel allogeneic cell therapies with γδ T cells? We find out!

February 26, 2019

A Voyage of Discovery

Can γδ T cells be employed as a therapeutic against cancer?

February 25, 2019

Window through the world of early STING agonist development

Targeting STING in cancer with a systemic small molecule approach? What's the story?

February 22, 2019

Can next generation STING agonism make a difference?

What does a next generation STING agonist look like and what issues is it attempting to address?

February 21, 2019

Insights on the STING agonist landscape

An in-depth look at the growing STING R&D landscape in oncology

February 20, 2019

ASCO GU19 Renal Cancer Review

What's hot in renal cancers? We take a look at what to expect at ASCO GU19 and offer insights on the emerging data

February 15, 2019

A look at what’s new in GU malignancies

What can we learn from the key trials being presented at ASCO GU19 in San Francisco?

February 14, 2019

New developments in Prostate Cancer

A review of key abstracts in prostate cancer expected at ASCO GU19 in San Francisco

February 13, 2019

New developments in Multiple Myeloma

We take a look at several key developments in myeloma on the antibody and cell therapy front.

February 11, 2019

Can we target p53 therapeutically?

What's new about p53 mutants and MDM2 inhibitors?

February 7, 2019

Book Review – L’Immunothérapie des cancers

Should you read a book on the History of Cancer Immunotherapy? Here's our review...

February 5, 2019

Ever decreasing circles in oncology R&D

Analysis and predictions of two oncology phase 3 readouts coming soon...

February 4, 2019

New developments in cytokines as immune modulators

New insights emerging from research on cytokines as an effective way to induce anti tumour immunity

January 31, 2019

How do we improve on 1st Generation T cell bispecifics?

An upcoming small biotech focused on IO targets with their novel platform approach

January 28, 2019

The Yin and Yang of biomarkers in cancer research

Some examples of potentially useful biomarker inclusion in early oncology trials

January 22, 2019

Insights from the ASCO GI19 conference

What to watch out for at the ASCO GI19 conference in San Francisco

January 17, 2019

A tale of two cities – a look at two small immunotherapy biotechs

Going beyond anti-PD1 checkpoint blockade is important if we want to help more people respond to cancer immunotherapy

January 14, 2019

TKIs are still alive and kicking!

Drugging the undruggable with creative approaches to molecule development

January 9, 2019

JPM19 Day 3 Highlights

Commentary on some up and coming biotechs in the oncology space

January 9, 2019

JPM19 Highlights from Day 2

Insights and commentary from the second day at #JPM19

January 8, 2019

JPM19 Highlights from Day 1

Insights and commentary from the first day of JPM19

January 7, 2019

A novel approach to cell therapy

Beyond T and NK cells, other immune cells can be used for cell therapies in solid tumours

January 4, 2019

The challenges of bispecifics

FDA slaps a partial clinical hold for unwanted side effects, now what?

December 11, 2018

SABCS18 An in-depth review of key breast cancer trials

A rock around the breast cancer clock with cancer immunotherapies and targeted agents from SABCS18

December 7, 2018

Potential of CAR T cell therapy in CLL

How do we improve CAR-T cell therapy in CLL? A look at clinical data plus a new thought leader interview in the space.

December 10, 2018

ASH18 Highlights from Day 3

Review of a round dozen key abstracts at #ASH18, both scientific and clinical data is under the microscope!

December 3, 2018

ASH18 Highlights from Day 2

We offer 13 key highlights from day 2 of ASH18, including some surprises.

December 2, 2018

ASH18 Highlights from Day 1

Highlights from Day 1 of the 2018 ASH conference held in San Diego

December 1, 2018

New developments in tumour immunology and immunotherapy

Highlights from the AACR special conference on tumour immunology and immunotherapy

December 1, 2018

ASH18 Preview 3 – BCMA

From one BCMA directed CAR in 2015, we now have a very competitive niche in multiple myeloma. What's in store?

November 26, 2018

ASH18 Preview 2 Late Breaking Abstracts

What to watch out for in the ASH18 LBA session

November 20, 2018

What can we learn from early IO trials?

There are a number of important lessons we can learn from early phase 1 trials. Here are some of them.

November 16, 2018

Learning from failure with IO combos

AstraZeneca miss on OS in the phase 3 MYSTIC trial – what next? At one point we were posting…

November 16, 2018

Pinning down potential new opportunities for IL–8 and 4–1BB

What is old is new again - a look at some forgotten oncology targets that are coming back in fashion

November 13, 2018

An analysis of Nektar’s latest PIVOT data and pipeline update

Update on PIVOT-02 with nivolumab plus NKTR-214 in 1L metastatic melanoma

November 12, 2018

How the microbiota impact response to cancer immunotherapy

The evolving story of how commensal microbiota can affect response to cancer immunotherapy

November 9, 2018

New developments in immune escape

Latest news and insights on immune escape mechanisms associated with cancer immunotherapy

November 8, 2018

Can CytomX’s Probody checkpoint beat the competition?

Can we improve on the tolerability of the nivolumab-ipilimumab regimen by designing better a checkpoint inhibitor?

November 5, 2018

SITC18 Preview and IO curiosities

An extensive round-up of what to expect from SITC18 ahead of the abstract reveal

November 2, 2018

Creating order from the ASH18 data dump

A top-line review of the ASH18 abstract palooza

November 1, 2018

Iraj Ali leads the way at Achilles Therapeutics

Achilles Therapeutics is an emerging biotech in the cell therapy space that is based on truncal neoantigens

October 31, 2018

What did we learn from Neon at ESMO18?

Initial results from the neon NEO-PV-01 phase 1B trial presented by Dr Patrick Ott

October 30, 2018

Is blood TMB ready for prime time?

With new data on the blood-based TMB test at ESMO, what can we learn about this approach?

October 29, 2018

Why are the SOLO1 data so compelling?

A discussion about the impact of the olaparib on the PARPi niche based on the findings of the SOLO1 trial

October 26, 2018

5 Trends from ESMO18

New trends in early drug develoment and Developmental Therapeutics

October 24, 2018

ESMO18 Live Blog Day 4

Wins for Pharma, some shakeouts for small biotechs on manic Monday at #ESMO18

October 22, 2018

ESMO18 Live Blog Day 3

Highlights and lowlights from Munich

October 21, 2018

ESMO18 Live Blog Day 2

Highlights and lowlights from Day 2 of #ESMO18

October 20, 2018

ESMO18 Live Blog Day 1

Highlights from Day 1 of #ESMO18 in Munich

October 19, 2018
View of Cambridge and Charles River

A new prime and boost cell therapy for treating cancer?

Can we use technology to squeeze more out of B cells to generate an army of killer T cells?

October 17, 2018

ESMO18 Preview 5 – A look at the evolving Renal Cell Carcinoma landscape

The changing face of renal cell cancer from several perspectives

October 16, 2018

An update on key SCLC trials

A look at the CheckMate-331 and CheckMate-451 study and other SCLC trials

October 12, 2018

ESMO18 Preview 4 Gems from the Poster Halls

A dozen poster abstracts to watch out for at ESMO18 on a wide range of topics...

October 11, 2018

ESMO18 Preview 3 Top 10 Oral Abstracts

Third ESMO18 preview on oral abstract presentations

October 8, 2018

New developments in neoantigen vaccines

A look a progress on NeoVax in GBM, RNA vaccines and even a novel CAR T cell therapy with a difference.

October 8, 2018

Update on CAR T cell therapies at CICON18

Some key notes on CAR T cell therapy developments ahead of SITC18 and ASH18

October 3, 2018

CICON18 Day 1 Highlights

Highlights from the first day of #CICON18 in New York

October 1, 2018

ESMO18 Preview 1 Late Breakers What To Watch Out For

ESMO18 Preview 1 - Late Breaking Abstracts to watch out for

September 26, 2018

WCLC2018 Roundup of key lung cancer data

After the WCLC2018 preview, what does the data actually teach us? A round up and commentary on 16 key trials

September 25, 2018

Preview of CICON18 – Part 2

Our second preview of what to expect at CICON18 - top 10 poster abstracts

September 24, 2018

Preview of CICON18 – Part 1

Part 1 of our #CICON18 Previews - a look at 11 intriguing IO related studies

September 20, 2018

An early cell therapy product to watch out for

Cell therapy is a very broad church - here's an interesting approach to keep an eye on

September 19, 2018

What was old in cancer research is new again

A fresh look at a class of targeted therapy agents that are beginning to look promising in some cancer patients

September 13, 2018

New Insights on BCMA BiTEs and CAR T cell therapies in Myeloma

Update on BCMA, SLAMF7 and other targets in multiple myeloma

September 11, 2018

Preview of WCLC 2018 – what’s new in lung cancer?

What to watch out for at WCLC2018 in Toronto later this month

September 6, 2018

New targets and indications in oncology R&D

Four areas of research in oncology R&D that may involve new targets or new indications emerging

September 5, 2018

Pathways to success with NK cell therapy

Will NK cell engagers have a positive impact on checkpoint therapy and other adaptive immunotherapies?

August 28, 2018

Learnings from IO combinations and where we’re headed

Lessons learned from recent failure and a look at where a few new developments might be coming from...

August 23, 2018

Armored CAR-T cell therapies and commercial threats from the East

On launched products, armored CARs and the potential threat from China

August 16, 2018

Targeting immunosuppression and other stories – are we ready for prime time yet?

On targeting immunosuppression and some obscure oncogenic targets

August 9, 2018

Picking PARP inhibitors apart

Are the PARPi a class effect or are there real differences between them that may become more apparent in future combo studies?

August 1, 2018

When oncogenic and immunogenic worlds collide…

Five key recent papers that are well worth looking at and what the science teaches us about next directions

July 25, 2018

An up and coming IO target to watch out for

Beyond PD-1 and CTLA4 there are other checkpoint and IO targets being investigated. We take a look at one of the promising ones...

July 19, 2018

Adapting TCR therapies for different solid tumours

An in-depth look at Adaptimmune's TCR T cell therapy program

July 10, 2018

Under the hood – a look at important new cancer research

Rumination, notes and updates on CAR-T cell therapy, checkpoint blockade, SCLC, genomics and TCR signalling...

June 25, 2018

Can we use exosomes for immune monitoring?

One of the ongoing challenges with cancer immunotherapy is monitoring response to treatment. Even if you…

June 21, 2018

In a Prudential Light

Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.

June 19, 2018

The Potential for Cytokines in Cancer Immunotherapy

The latest part in our cytokine mini-series explores the potential for incorporating them in CARs or combining with checkpoint blockade through the lens of an expert in the field...

June 18, 2018

Fearful Symmetry

Where are Blueprint going with their various programs involving targeted therapies in a range of different cancers?

June 15, 2018

How should we interpret the NKTR–214 data presented at ASCO?

What can we learn from the updated Nektar NKTR-214 data presented at #ASCO18?

June 14, 2018

A beautiful day

Update on TLR9 as a target and what we learn from the latest clinical data

June 12, 2018

Fitting it all together – what does the post ASCO Lung Cancer Landscape look like?

Thoughts, reflections and learnings from the recent phase 3 lung cancer readouts from a lung cancer specialist...

June 11, 2018

ASCO18 Review of targeted therapies and combination approaches

Highlights and Lowlights amongst targeted therapy data at ASCO 2018

June 7, 2018

ASCO18 Day 3 Highlights and Lowlights

Ongoing discussion and debate about data in lung cancer and up and coming innate immunotherapies that may move the needle in IO-IO combos.

June 5, 2018

Will KEYNOTE-042 change the standard of care in lung cancer?

Dr Gilberto Lopes discusses the KEYNOTE 042 and 189 trials in first-line non-small cell lung cancer (NSCLC).

June 3, 2018

ASCO18 Day 1 Highlights

The promise and pitfalls of Day 1 of #ASCO18

June 3, 2018

Why don’t all cancer patients with a high TIL respond to immunotherapy?

We explore the importance of looking under the hood at various expression levels...

May 30, 2018

Learning from IO-IO combo misses

Not all IO-IO combos will be successful in solid tumours, what can we learn from the Genmab-Janssen news for daratumumab in NSCLC?

May 29, 2018

ASCO18 Reader Q&A

It’s a Bank Holiday weekend on both sides of the pond, which is always a good excuse for some…

May 25, 2018

ASCO18 Preview on Biomarkers of Response

Can TMB replace PD-L1 as a predictive biomarker of response for immune checkpoint blockade therapy?

May 22, 2018

ASCO18 Preview 4 What’s Hot in Urothelial Carcinoma

A preview of key abstracts in urothelial and bladder cancer expected to be presented at ASCO18

May 21, 2018

ASCO18 Preview 3 – Take a Walk on Life

What do we learn from the ASCO abstract release? Quite a lot! Here we debunk some of the controversial issues and inaccuracies that have arisen

May 18, 2018

ASCO18 Preview 2 – a dozen key Posters to watch out for

Key themes and topics of interest in the poster halls - what stands out amongst several thousand posters?

May 16, 2018

ASCO18 Preview 1 – Magnificence or Atrocious?

What to watch out for at ASCO18 in the oral presentation sessions

May 15, 2018

Development of Next Generation CAR T cell therapies

A look at the history of CAR T cell therapy design and where things are headed in the future with one of the original cell therapy pioneers

May 14, 2018

An up and coming new player in CAR T cell therapy

A look at path to market strategies open to a small biotech in the CAR-T cell space

May 9, 2018

A different take on targeting cancer

How do we drive more T cells into the tumour? Here's one company who are looking to do just that.

May 8, 2018

A new inhibitory checkpoint target hits the clinic

Going beyond PD-1, PD-L1 and CTLA-4 to explore other inhibitory checkpoint targets that may be useful in the clinic

May 7, 2018

Stacking up evidence from IO clinical trials

A look at various lessons from recent IO trials and how they can applied to new readouts expected at ASCO18

May 3, 2018

Bench to bedside and back again

A look at how basic and translational evidence points towards TGFβ as a possible new target for IO combos in some tumour types

May 1, 2018

Targeting TGF-β and the tumour microenvironment

A look at one way with which we can target the tumour microenviroment to improve response of cancer immunotherapy

April 30, 2018

How Charles Swanton plans to revolutionize treatment of Lung and Renal cancers

What can we learn from the TRACERx studies in lung and renal cancers? Quite a lot, it seems...

April 26, 2018

The PD-1 Gorilla is Back!

4 KOLs tell us what they really thought about the 3 studies in 1L NSCLC presented at AACR18

April 25, 2018

Can TMB help select patients for lung cancer therapy or not?

A look at TMB as an emerging biomarker for cancer immunotherapy - is it ready for prime time?

April 23, 2018

To be or not to be…

Answering questions on the 1L NSCLC data presented at #AACR18

April 17, 2018

AACR18 Red and Green Flags in 1L NSCLC

A look at the latest 1L NSCLC trial readouts

April 16, 2018

AACR18 Day 2 Highlights

A look at the Class of 2018 new products in development - a hit or miss?

April 16, 2018

AACR18: Day 1 Cancer & Immunology Symposium

A look at some new - and very early - directions in CAR T cell therapies, especially in solid tumours.

April 15, 2018

An under-appreciated oncology drug class

How can we improve on monotherapy with PARP inhibitors? How do we address primary and acquired resistance?

April 10, 2018

The path to success in 1L NSCLC

Will the results from Merck's KEYNOTE-042 study change practice in 1L NSCLC?

April 9, 2018

AACR18 Preview 6: Beyond epacadostat and a look at early IO-IO combinations

Beyond the news that Incyte and Merck's epacadostat plus pembrolizumab combo failed to hit its endpoints in advanced melanoma, what other IO-IO combos should we turn to?

April 6, 2018

AACR18 Preview 5: is TGFβ an emerging cancer target?

A look at an emerging IO target that might be useful in ceratin tumour types and patient subsets when given in combination

April 4, 2018

AACR18 Preview 4: a look at new developments in a key tumour type

What's hot at #AACR18 in terms of data to watch out for in a certain tumour type?

April 3, 2018

Can we predict early treatment discontinuation on immune checkpoint therapy?

A look at the clinical features that predict for early discontinuation with checkpoint blockade in ovarian cancer

March 28, 2018

Innate Pharma – converting science into the clinic

An in-depth look at the French biotech company Innate Pharma and where they are now two years on from our last look at their IO pipeline.

March 27, 2018

A potentially encouraging IO combination approach

What can we learn from the early data exploring PARPi plus checkpoint blockade combinations in ovarian cancer?

March 26, 2018

Is there a silver lining in SCLC?

A post mortem of the Rova-T TRINITY trial and a look to the future in SCLC

March 22, 2018

The squamous and non-squamous lung cancer race continues!

A look at the key lung cancer data expected at AACR18 and what to expect from the latest squamous NSCLC

March 21, 2018

Exploring Gamida Cell with Dr Julian Adams

A look at what Gamida Cell, an up and coming cellular and innate immunotherapy company are up to...

March 15, 2018

Targeting NK cells effectively in AML

A look at targeting NK cells with immune agonists, cytokines and adoptive cell therapies

March 14, 2018

A look at NK cells – an interview with Dr Michael Caligiuri

A look at the history of NK cell development and where we're going in future with this IO approach

March 7, 2018

Challenges and Opportunities with NK cells for cancer therapeutics

Our latest primer explores NK cells and their role in oncology R&D - it's an up and coming area

March 5, 2018

New Horizons in Pancreatic Cancer

Some key highlights from the recent inaugural pancreatic cancer symposium in Houston

March 2, 2018

Potential of Exosomes in Pancreatic Cancer

A look at an emerging area for biomarkers and stealth cancer therapeutics

March 1, 2018

Why we should be cautious about IO-IO combination trials

A look at some of the issues underlying IO-IO combos and whether they can help us assess if these trials will succeed - or not.

February 28, 2018

Are fast or slow CARs better for the future?

In this post, we take a look at new clinical and scientific findings that may pave the way forward for the future in the CAR T cell space

February 26, 2018

Future of CAR T Cell Therapy for Leukemia and Lymphoma

What did Dr Grupp and Dr Komanduri learn from participation in the CAR T cell therapy trials?

February 22, 2018

Update on cytokines as novel cancer immunotherapy

A look at innate approaches to stimulating the immune system including IL-15 agonists

February 21, 2018

Pathways to success targeting CD47-SIRPα

Insights from researchers in the CD47 niche - what do they really think?

February 20, 2018

A look at the controversial CD47-SIRPα landscape

A look at the players in controversial CD47-SIRPα landscape

February 15, 2018

How will the RCC landscape change – who dares, wins?!

A look at the changing face of the RCC landscape, including current and near term trial readouts

February 13, 2018

The death of PD-L1 in urothelial cancer

As inconsistent data abounds, is it time to move on from PD-L1 as a biomarker of response to checkpoint blockade?

February 12, 2018

Future directions in advanced prostate cancer

A look at some new targeted and IO combinations in development for advanced prostate cancer

February 9, 2018

Apalutamide is not a winner at ASCO GU

Will apalutamide and enzalutamide make headway in the M0 prostate cancer setting?

February 8, 2018

Flying high with the controversial CD47-SIRPα pathway in cancer

A look at biology behind targeting CD47 in cancer and some of the controversies plaguing the space

February 7, 2018

GU18 Preview – Promise and Pitfalls Abound

Highlights and Lowlights from ASCO GU 2018 - what to watch out for.

February 5, 2018

Go Forth and PROSPER

Interview with Dr Daniel George on Phase 3 PROSPER trial results

February 5, 2018

A look at the controversial BMS trial CheckMate-227 in lung cancer

BMS announced that CM-227 hit PFS in lung cancer patients with high tumour mutation load, now what?

February 5, 2018

How Will Adoptive Cell Therapy Crack Solid Tumours?

A look at Dr Malcolm Brenner's work on virus specific T cell therapies

January 31, 2018

Bad news for Bellicum and BPX-501

FDA places Bellicum's BPX-501 on clinical hold - what's the story and what's next?

January 30, 2018

Report on key data in GU Cancers from ASCO-SITC 2018

At ASCO-SITC this weekend there was some compelling new scientific data highlighting subsets of patients who might be eligible for cancer immunotherapy, including novel combination approaches.

January 30, 2018

The STING and Metastasis Controversy Reignited

Expert interview with Dr Glen Barber reignites the controversy over whether STING agonists could cause metastasis in cancer patients.

January 29, 2018

Immune Landscape of Pancreatic Cancer

A look at where we are in pancreatic cancer and how the landscape has evolved of late...

January 25, 2018

A look at an up and coming west coast biotech

A look at the pipeline of the up and coming Seattle biotech, Alpine Immune Sciences

January 22, 2018

Can STING agonists promote cancer metastasis?

Can STING agonists promote cancer metastasis in some patients? That's one of the key questions from new research linking chromosomal instability with tumor metastasis through activation of the cGAS-STING pathway.

January 23, 2018

PharmaMar’s lurbinectedin misses in platinum-resistant ovarian cancer

PharmaMar's lurbinectedin misses in phase 3 platinum resistant ovarian cancer

January 18, 2018

ASCO GI18 Preview

A look at 8 key abstracts being presented at #GI18 in San Francisco this week.

January 17, 2018

Tears Before Bedtime…

How does positive trials from Roche and Merck impact the 1L NSCLC landscape?

January 16, 2018

How Obsidian could revolutionise CAR T cell therapy in solid tumours

A look at how new approaches in synthetic biology could revolutionise cell therapy in solid tumours

January 10, 2018

JPM18 Healthcare Day 3 Highlights

Commentary on Day 3 at 2018 JP Morgan Healthcare Conference in San Francisco

January 10, 2018

Syros CEO Nancy Simonian looks forward to an exciting 2018

Interview with Syros Pharma CEO Dr Nancy Simonian

January 9, 2018

Highlights of JPM18 Healthcare Day 2

Commentary on Day 2 of the 2018 JP Morgan Healthcare Conference in San Francisco

January 9, 2018
San Francisco Trolley Car

Highlights of JPM18 Healthcare Conf Day 1

Commentary on Day 1 of the 2018 JP Morgan Healthcare Conference in San Francisco

January 8, 2018

Key trends in oncology R&D for 2018 – Part 1

New series on Key Trends in Oncology for 2018

January 4, 2018

A competitive threat to CAR T cell therapy in aggressive lymphoma

New approaches that enter a market unexpectedly can disrupt the status quo and push out more severe therapies to later lines of treatment

January 3, 2018

The Future of Multiple Myeloma

A look at key pipeline developments in multiple myeloma through the lens of a global expert in the field

January 2, 2018

The science behind the venetoclax clinical trial strategy

Where is the venetoclax BCL-2 program going in hematologic malignancies?

December 18, 2017

ASH17 masterclass with Dr John Leonard on lymphomas

An interview with Dr John Leonard exploring his thoughts on some of the key lymphoma data at #ASH17

December 14, 2017

ASH17 Will MURANO impact the CLL landscape?

As we see new readouts emerge with different doublets and triplets in CLL, how will they impact the treatment landscape?

December 13, 2017
Snow at GWCC

Commentary on ASH17 Day 2 in Atlanta

Commentary on Sunday at 2017 ASH annual meeting in Atlanta

December 10, 2017

ASH17 – Day 1 Highlights and Lowlights

A look at some of the sessions and learnings from the first day at ASH 2017

December 9, 2017

A potential new IO combination for clinical development

People love hearing about new or emerging cancer targets - there's always the hope that one might find something cool that could move the needle and really make a difference...

December 8, 2017

IMpower150 lung cancer trial provides a window to the Future of Immunotherapy

The first phase 3 trial in 1L NSCLC to hit the PFS endpoint is Genentech's IMpower150. What can we learn from this study?

December 7, 2017

SABCS17 Update on CDK4/6 Inhibitors

A look at the latest CDK4/6 inhibitor data including the important phase 3 trial with ribociclib (MONALEESA-7).

December 6, 2017

ASH17 CAR T cell therapy Preview

A look at what's hot in CAR T cell therapies at #ASH17

December 4, 2017

Top 10 #ASH17 abstracts to watch out for

The Mav's key oral abstracts to follow at #ASH17 -- warning this list includes quirky selections!

November 30, 2017

ASH Preview 2 – Developmental Therapeutics

A look at a selection of promising Developmental Therapeutics abstracts from ASH17 - what's in store this year?

November 29, 2017

What can genomics and tumours teach us about cancer drug development?

A look at loss of heterozygosity and what it means for new lung cancer therapies

November 20, 2017

All that you leave behind

Integrated biomarker approaches are beginning to emerge to help researchers segment patients better for appropriate therapy. Here's one approach...

November 16, 2017

Why we should be cautiously optimistic about the cabiralizumab plus nivolumab data in pancreatic cancer

A look at the cabiralizumab plus nivolumab combination in PDAC at SITC over the weekend

November 15, 2017

Can entinostat overcome resistance to pembrolizumab?

A look st Syndax's entinostat and what happens when given in combination with pembrolizumab in melanoma and lung cancer

November 14, 2017

Nektar hits it out of the park at SITC 2017

A look at Nektar's promising IO portfolio and what's next for the up and coming biotech

November 13, 2017

The Stars from Day 2 of SITC17

Ten stars from the clinical presentations on Day 2 of SITC 2017

November 12, 2017

Interview with Dr Stephan Grupp on the JCAR015 ROCKET trial

A CAR T cell therapist's perspective on the Juno JCAR015 ROCKET dataset

November 11, 2017

SITC17 DAY 1 Highlights and Lowlights

A look at some of the main events from the first day at SITC 2017 - including Juno's ROCKET data.

November 10, 2017
National Harbor from Gaylord Hotel

SITC17 – Final Look at what to watch out for

Final SITC17 Preview and a look at key talks now that the abstracts are available.

November 8, 2017

TARGETS17 Gems from the Poster Halls

A look at new targets, molecules and approaches to cancer research from #TARGETS17 in Philly

November 7, 2017

Some simply stunning cancer research for Journal Club

Science Fridays: A look at six key studies recently published on cancer research that BSB readers can learn from.

November 3, 2017

ASH17 Preview of emerging therapies for Aggressive Lymphomas

A look at up and coming emerging therapies in the DLBCL space

November 1, 2017

Key Highlights from Day 3 at AACR-NCI-EORTC TARGETS17

Highlights from Day 3 of the AACR-NCI-EORTC Molecular Targets meeting in Philadelphia

October 29, 2017

Key Highlights From AACR Molecular Targets Day 1

Commentary on Day 1 of 2017 AACR NCI EORTC Molecular Targets and Cancer Therapeutics Conference in Philadelphia

October 27, 2017

SCLC – An in-depth look at ROVA-T and TRINITY

A look at ROVA-T's chances in the upcoming phase 2 TRINITY trial readout

October 25, 2017

A look at the SCLC Landscape and Rova-T

A look at the SCLC landscape including some promising new developments

October 24, 2017


A look at the trials and tribulations for Immune Design's CMB305 and what's the latest in 1L NSCLC

October 20, 2017

Going beyond PD-L1 expression as a immune biomarker

What other approaches might be useful for predicting response (or non-response) to cancer immunotherapies?

October 19, 2017

Update on CD123 and other viable targets in AML

With increasing evidence that CD123 is a suboptimal target in AML, what other approaches might be more useful to consider?

October 17, 2017

SITC 2017 What to Watch for in Late Breaking Posters

A look at some of the LBA posters to be presented at #SITC17 in November

October 16, 2017
National Harbor Maryland

Five key late breakers to watch out for at SITC17

A look at 5 key oral late breakers at #SITC17 and what to expect or watch out for

October 13, 2017

Targeting Natural Killer Cells in Cancer Immunotherapy

Can we address inhibitory factors that dampen NK cells to enhance the anti-cancer effect on tumours?

October 11, 2017

Red and green flags in 1L NSCLC trials

Our latest predictions in 1L NSCLC and what to expect from the upcoming trial readouts in this niche

October 10, 2017

Immunotherapy Possibilities in Pancreatic Cancer

A look at what's different about exceptional responders in PDAC and what can we learn about neoantigen approaches here?

October 5, 2017

The Future of Cancer Vaccines Part 5 – An Interview with Prof George Coukos

A look at the latest developments in cancer immunotherapy in ovarian cancer, with a particular focus on neoepitopes and cancer vaccines.

October 3, 2017

The Future of Cancer Vaccines Part 4 – An Interview with Prof Kees Melief

Interview with Prof Kees Melief, CSO ISA Immune System Activation Pharmaceuticals

October 2, 2017

The Future of Cancer Vaccines Part 3 – Interview with Prof Ugur Sahin

A look at Ugur Sahin's BioNTech and personalized mRNA vaccines

September 28, 2017

The Future of Cancer Vaccines Part 2 – interview with Dr Ira Mellman

Genentech have several cancer vaccine collaborations in place, where do they see the future going in this niche?

September 27, 2017

The Future of Cancer Vaccines – An Interview with Dr Cathy Wu

Part 1 of a new mini-series on cancer vaccines. This one covers an update on Neon's neoantigen approach...

September 26, 2017

Hyperprogression – is it real or fake news?

After pseudoprogression, the IO field has moved onto hyperprogression. What is it and why does it matter?

September 25, 2017

How to disrupt the CAR T cell therapy space

Is the CAR T cell therapy space ready for disruption? At least one researcher thinks so. What does this entail?

September 21, 2017

PROSPECTing for nuggets with PROSTVAC in CRPC

A post mortem analysis of the Bavarian Nordic PROSTVAC cancer vaccine trial failure in CRPC

September 15, 2017

Can this novel combination overcome resistance to checkpoint blockade?

An early look at a new IO combination that may help overcome resistance to checkpoint therapy

September 14, 2017

ESMO17 Day 4 Highlights and Lowlights

A look at the last day of ESMO17 with key data on cancer vaccines, checkpoint and targeted therapies to explore

September 12, 2017

ESMO Day 3 Highlights and Lowlights

A roundup of the key trials and targets presented on Sunday at #ESMO17

September 10, 2017

ESMO17 Day 1 Highlights and Lowlights

A look at mostly lung cancer highlights from the first 2 days at #ESMO17

September 9, 2017

The changing face of ovarian cancer

Rucaparib likely joins the early maintenance PARP club in ovarian cancer with their ARIEL3 data at #ESMO17

September 7, 2017

ESMO Preview 5 – intriguing small biotech immunotherapies

A look at some of the small biotechs and what they're developing on IO front that looks intriguing at #ESMO17

September 6, 2017

ESMO Preview 4 – Rock around the clock

8 key ImmunoOnc studies being presented at #ESMO17 this month

September 4, 2017

Is CD123 a good target in AML?

A look at what's happening with Cellectis and their clinical trial program with CD19 and CD123 CARs.

August 31, 2017

The dawn of a new beginning for Cellectis?

What does the future hold for Cellectis and allogeneic "off the shelf" CAR T cell therapy?

August 30, 2017

Waseem Qasim Pioneers Allogeneic CAR T Cell Therapy

Gene editing looks set to become entrenched in allogeneic CAR T cell development, so what's new?

August 29, 2017

A man on a Mission to #FinishCancer

Does timing and sequencing of immune agonists impact their effect when given with checkpoint blockade?

August 28, 2017

ESMO17 Preview 3 – A look at HCC and Blueprint’s BLU-554

A look at the changing HCC market and how pipeline agents may (or may not) impact the landscape...

August 24, 2017

August 2017 BSB Journal Club on Breast Cancer

After recent readouts of breast cancer trials at #ASCO17, where do we go next for future combos? Based on recent preclinical research, we have some ideas...

August 22, 2017

ESMO17 Preview 2 – The 5 on Targeted Therapy

An eclectic selection of important abstracts involving targeted therapies to watch out for at #ESMO17

August 17, 2017

A look at CheckMate-214 in 1L metastatic RCC

A look at the interim results from the BMS CheckMate-214 trial in renal cell carcinoma

August 16, 2017

ESMO17 Preview 1 – The IO 5

Top 5 IO oral abstracts to watch out for in Madrid

August 15, 2017

How to revolutionize cancer immunotherapy trials

A look at various factors that can influence cancer immunotherapy trials through the lens of an immunologist

August 10, 2017

Exploring pre-existing immunity in cancer immunotherapy trials

A look at the role of pre-existing immunity in cancer immunotherapy trial readouts at ASCO17

August 8, 2017

Jumpstarting the immune system with synthetic immunity

Jumpstarting the immune system with a synthetic immunity approach - how can we do this?

August 2, 2017

A hidden gem at ASCO17

How can we boost the efficacy of checkpoint therapies? One way is to drive more activated T cells into the tumour.

August 1, 2017

MYSTIC Interim Analysis July 2017 shows PFS Miss

A look at AZN's miss with their IO-IO combination in 1L NSCLC

July 27, 2017

A look at why we get mixed results with phase 3 checkpoint trials

A look at why checkpoint therapy trials might be giving us inconsistent results of late

July 25, 2017

A look at Nektar Therapeutics immunotherapy pipeline

Update on Nektar Therapeutics IO portfolio and a look at their burgeoning autoimmune disorder pipeline

July 24, 2017
Berlin Wall Museum

Can we use immunotherapy to treat or delay Alzheimers Disease?

How we could use our immune system against Alzheimer's?

July 20, 2017

Can epigenetic therapy boost cancer immunotherapy?

A look at the intersection of epigenetics and cancer immunotherapy - what can we learn and where are we going in this niche?

July 19, 2017

Predictions in 1L NSCLC trials

A second look at the evolving 1L NSCLC landscape with a focus on MYSTIC and IMpower150

July 17, 2017

Paris Immuno-Oncology Summit 2017

Commentary on 2017 Paris Immuno-Oncology summit organised by European Academy of Tumor Immunology and Miltenyi Biotec

July 10, 2017

July Journal Club

July Journal Club explores some intriguing new data around a cancer immunotherapy theme

July 7, 2017

When targeted and immunotherapy worlds collide

A look at an up and coming small cap biotech developing targeted and immunotherapy agents for the treatment of cancer.

July 6, 2017

EACR17 Cancer Genomics Day 3

Notes on HGSOC, melanoma resistance and the evolution of NSCLC...

June 29, 2017
Punting on River Cam, Cambridge

EACR Cancer Genomics Day 2

Coverage of European Association for Cancer Research EACR cancer genomics conference at Churchill College, Cambridge

June 28, 2017

Why did Atezolizumab fail in advanced Urothelial Bladder Cancer?

Why did the IMvigor211 phase 3 trial with atezolizumab in UBC fail? BSB spoke to Prof Tom Powles.

June 27, 2017

EACR Cancer Genomics Day 1 Update #CG17

Commentary from Day 1-2 of the 3rd EACR meeting on Cancer Genomics

June 27, 2017

Gems from the ASCO17 Poster Hall Part 1

A look at how liver mets can negatively impact cancer immunotherapies

June 22, 2017

Can a vaccine make a difference in sarcoma?

What can we learn from the Immune Design data in sarcomas with their NY-ESO-1 vaccine?

June 21, 2017

New developments in sarcoma

What's new in the sarcoma space? Which novel approaches are worth watching out for?

June 20, 2017

A promising IO combo approach to watch out for

Overcoming resistance to monotherapy treatment with checkpoint blockade is crucial for success with IO combos. Here's one potential solution...

June 19, 2017

APHINITY – How much better and for whom?

Thought leader reactions and sentiments to the APHINITY readout in adjuvant HER2+ breast cancer

June 16, 2017

New IO developments in breast cancer

A look at checkpoint blockade in early stage breast cancer - encouraging or not?

June 14, 2017

Going beyond PARP monotherapies

A look at PARP as it journeys from 1999 to 2017 culminating in a plenary presentation at ASCO

June 13, 2017

An in-depth look at OLYMPIAD in HER2 negative breast cancer

Olaparib is the first PARP to demonstrate a clinical benefit in HER2- breast cancer - what do KOLs really think?

June 12, 2017

Novartis JULIET trial and other CAR-T cell issues

A look at the initial results from the Novartis CTL019 pivotal trial in aggressive lymphoma (JULIET).

June 8, 2017

Trends, Highlights and Lowlights from ASCO 2017

Beyond the incremental improvements seen in clinical trials, what are the new trends emerging from ASCO 2017 that will impact oncology R&D?

June 6, 2017

ASCO17 Preview A Strategic Look at Emerging Themes

Right now many people are overwhelmed not just with the sheer number of ASCO abstracts to process and…

May 31, 2017

ASCO17 Top 10 Abstracts

Our Top 10 #ASCO17 abstracts to watch out for

May 26, 2017
Chicago River

ASCO 2017 CAR T Cell Therapy Preview

Some intriguing surprises in the CAR T cell therapy abstracts this year...

May 24, 2017

$PBYI – plain sailing or death by a thousand cuts?

A look at the FDA briefing docs on Puma's neratinib

May 23, 2017
ASCO 2014 Chicago Contemplation

An up and coming area in early oncology R&D

A look at an up and coming niche in cancer research that may turn out to be useful in conjunction with checkpoint blockade

May 22, 2017

5 key abstracts to consider from ASCO 2017

A look at 5 key abstracts that tickled my fancy from #ASCO17; Warning - not all are positive!

May 18, 2017

ASCO 2017 Preview 2 – IDO1 Inhibitors

Update on #ASCO17 data for IDO1 inhibitors in various cancers

May 17, 2017

Things we need to think about ahead of ASCO17

A fireside chat with a leading KOL involved in cancer research on resistance.

May 16, 2017

Can AstraZeneca leapfrog the competition in lung cancer AGAIN?

Durvalumab grabs pole position in unresectable NSCLC amongst IO compounds

May 12, 2017

On Kite’s cerebral edema and Genentech’s IMvigor211 miss

We've been overdue a correction in the irrational exuberance around IO... is this the tip of the iceberg?

May 10, 2017

Going Beyond PARP in DNA Damage Repair

A look a one company's approach to DDR and potential combination opportunities in this niche

May 9, 2017

On Gritstone and neoantigens

A look at a promising biotech in the neoantigen space - what's their approach and how might it fare?

May 4, 2017

Do Exosomes Matter?

With 'liquid biopsies' on the rise, we take a look at another potential candidate that could be useful - exploring exosomes.

May 2, 2017

How do we get cancer immunotherapy to work in Prostate Cancer?

A candid look at new approaches being explored in cold tumours using prostate cancer as an example

May 1, 2017

BSB Mailbag on ROS1, ALK and TRK inhibitors

BSB Reader Mailbag on TRK/ROS1/ALK inhibitors

April 28, 2017

Can Jonathan Lim ignite the TRK oncology space?

An interview with Dr Jonathan Lim, Ignyta on TRK/ROS/ALK inhibition

April 26, 2017

Can AZN take immuno-oncology to the next level?

Through the keyhole with a look at AZN and MedImmune's IO portfolio

April 25, 2017

What do we know about Resistance to Checkpoints in Lung Cancer?

Expert interview at AACR17 with Dr Julie Brahmer on lung cancer immunotherapy resistance and preview of ASCO17 abstracts

April 20, 2017

Potential of CAR T cell therapy targeting Glioblastoma

Encouraging new developments in GBM with a novel CAR T cell therapy

April 18, 2017

Overcoming Cancer Immunotherapy Resistance

How do we overcome resistance to cancer immunotherapies? Here, we have an in-depth interview with a thought leader in this space.

April 17, 2017

Dan Chen outlines his vision for the Future of Cancer Immunotherapy at AACR17

Dr Daniel Chen from Roche/Genentech shares his vision for the future of cancer immunotherapy at AACR17.

April 13, 2017
AACR17 audience

Five Emerging Cancer Research Trends at AACR17

Five emerging cancer research trends we picked up at AACR17 that you should be aware of.

April 11, 2017

What does atezolizumab TNBC data presented at AACR17 tell us about breast cancer immunotherapy?

Interview with Professor Peter Schmid, Barts Cancer Institute.

April 10, 2017

Corvus CPI-444 Data Disappoints at AACR 2017

Commentary on Tuesday at 2017 AACR annual meeting in Washington DC.

April 5, 2017

A Busy Monday at AACR 2017

Commentary on Monday at the 2017 AACR annual meeting.

April 4, 2017

Sunday at AACR 2017 annual meeting

Commentary on Sunday at the 2017 AACR annual meeting

April 3, 2017

Reflections on Saturday at AACR17

Highlights from Day 1 at AACR17

April 1, 2017

AACR 2017 Preview 10

A look at some of the key sessions featuring checkpoint blockade at the AACR 2017 annual meeting

March 29, 2017

FDA Approval of Niraparib is a Failure for Precision Medicine

The third PARP inhibitor in ovarian cancer hits the market - what's the latest story?

March 27, 2017

AACR 2017 Preview 9

A comprehensive review of the key abstracts in the CAR T cell therapy niche and hints of the latest emerging trends

March 23, 2017

AACR 2017 Preview 8

A look at how research into transcription factors, super enhancers, chromatin regulation and broom/chromodomains is changing the way we look at cancer

March 22, 2017

AACR 2017 Preview 7

With increasing competition in the CDK4/6 space in HR+ HER2- metastatic breast cancer, how are things shaping up?

March 21, 2017

Asking Good Questions is both an Art and a Science

Latest BSB reader Q&A looks at 5 questions from subscribers

March 16, 2017

AACR 2017 Preview 6

A look at a new area of immune-oncology that looks set to be in the consciousness more over the next few years

March 15, 2017

AACR 2017 Preview 5

PARP! PARP! What's hot in ovarian cancer at SGO and AACR?

March 13, 2017

AACR 2017 Preview 4

Overcoming immune suppression in the tumour microenvironment

March 9, 2017

AACR 2017 Preview 3

After exploring a mechanistic approach and a tumour type as part of our AACR annual meeting coverage, in…

March 8, 2017

AACR 2017 Preview 2

A look at some recent clinical data and what we can learn from the new data expected at AACR in DC

March 7, 2017

AACR 2017 Preview 1

The first of our strategic and thematic AACR Previews for the 2017 annual meeting is here

March 6, 2017

Important ASCO-SITC 2017 Highlights and Trends

6 key trends and highlights of note from the inaugural ASCO-SITC meeting in Orlando, Florida

March 3, 2017

JCAR015 is dead. Long live JCAR015

After a rocky 2016, what does 2017 hold for Juno as they switch focus from JCAR015 to JCAR017?

March 1, 2017

Novel Way to Improve Checkpoint Inhibitor Efficacy

A look at another surprising factor that might affect efficacy of cancer immunotherapy and checkpoint blockade.

March 1, 2017

A novel immune checkpoint target

After JAK1/2 upregulation and PTEN loss, a third mechanism of resistance to checkpoint blockade has been identified. We discuss the issues around this latest challenge...

February 28, 2017

BMT Tandem Cell Therapy Insights

Insight from BMT Tandem 2017 meeting into latest Cell Therapy data

February 27, 2017
Ira Mellman Dan Chen Authors of Cancer Immunity Cycle

Understanding the Cancer-Immune Set Point

A look at cancer immunity and the new framework for exploring the cancer-immune setpoint.

February 22, 2017

Is 2017 the Year of the Cancer Vaccine?

A look at another approach for turning cold into hot (or warmer) tumours with cancer vaccines.

February 21, 2017

Blueprint Shows Promise in GIST and HCC

Targeted therapies aren't dead yet - oncogenic drivers are still important in many cancers. Here we look at progress in GIST, systemic mastocytosis and HCC...

February 16, 2017

A completely novel approach to targeting hematologic malignancies

A look at the deeper side of research - how the spliceosome and RNA splicing may be useful in cancer research.

February 15, 2017

On APHINITY, SOLO2 and Immunomedics

Reader Q&A on women's cancers relating to HER2, PARP and TNBC...

February 13, 2017

Journal Club – February 2017

A look at what we can learn from some recently published new papers in the oncology space.

February 9, 2017

Novel Targets in Multiple Myeloma

Going beyond proteasome inhibitors and IMiDs in multiple myeloma - what novel targets are attractive?

February 8, 2017

Targeting the tumour environment in Lymphomas

What we learnt at ASH16 on how to better target the tumour microenvironment in lymphoid malignancies.

February 6, 2017

How to improve response rates with targeted therapies in oncology

Exploring clinical trials with targeted therapies, including PARP and ATR inhibitors and combination approaches

February 2, 2017

A manifesto for immuno-oncology research

A draft manifesto for IO in cancer research and what we need to learn

February 1, 2017

Is Tucatinib better than Neratinib in HER2-positive Breast Cancer?

2017 could well turn out to be a good year for HER2+ breast cancer with several new developments ongoing. We take a look...

January 30, 2017

ASCO GI17 Gems from the Poster Hall

A look at gems from the #GI17 poster halls or molecules destined for Dog Drug Heaven?

January 27, 2017

New developments in advanced colorectal cancer

A couple of trials at ASCO #GI17 look promising in terms of trial design with encouraging implications for the future in metastatic colorectal cancer.

January 26, 2017

Will nivolumab make an impact in gastric cancer?

Will gastric cancer be one of the next indications for nivolumab?

January 25, 2017

Understanding the Mutational Landscape of Metastatic Breast Cancer

How crowdsourcing data from breast cancer patients may help future clinical R&D

January 24, 2017

Targeting Breast Cancer Stem Cells

Will cancer stem cell therapeutics impact the lives of people with metastatic breast cancer?

January 23, 2017

Can we expect more surprises in 1L NSCLC?

A look at the how several major phase 3 trial readouts will affect the 1L NSCLC landscape

January 18, 2017

Challenges and Opportunities in Inflammatory Breast Cancer

SABCS16 expert interview on Inflammatory Breast Cancer with Dr Naoto Ueno from MD Anderson Cancer Center.

January 17, 2017

How circulating tumor DNA could change cancer treatment

SABCS16 expert interview on the potential of circulating tumor DNA to change the treatment of cancer.

January 16, 2017
View of Cambridge and Charles River

Does Neon Therapeutics lead the Neoantigen field?

Update on Neon Tx as they move into commercial new product development with their neoantigen platform.

January 13, 2017
Dr Leisha Emens SABCS16

Advances in Breast Cancer Immunotherapy

Second in our series of expert interviews from the 2016 San Antonio Breast Cancer Symposium features Dr Leisha Emens

January 13, 2017

Still looking for a JPM17 Licensing Deal? How about a First-in-Class Drug for Metastatic Breast Cancer?

First in a mini-series of expert interviews from the 2016 San Antonio Breast Symposium #SABCS16 with a leading researcher who has discovered a first-in-class compound with potential in metastatic breast cancer.

January 12, 2017
SF Streetcar at Pine St

JPM17 Healthcare Conference Day 3 Highlights

Commentary on Wednesday at JPM17 in San Francisco

January 11, 2017
San Francisco Streetcar in Rain

Highlights of JPM17 Healthcare Conference Day 2

Commentary on Day 2 of the 2017 JP Morgan Healthcare Conference in San Francisco

January 10, 2017
San Francisco Streetcar

Highlights of JPM17 Healthcare Conference Day 1

Commentary around some of the corporate presentations at Day 1 of the 2017 JP Morgan Healthcare conference in San Francisco.

January 9, 2017

The future of CAR T cells in pediatric ALL

Interview with Dr Stephan Grupp on the data he presented at ASH16 and what the future may hold for CAR T cell therapy in pediatric ALL

January 9, 2017

Promising new agents to watch out for in Chronic Lymphocytic Leukemia

A look at some promising agents in new product development emerging in early CLL trials

January 6, 2017

The Changing CLL Landscape Part 1

How are recently approved novel therapies impacting the CLL landscape and where are we going next?

January 5, 2017

Does Polatuzumab Vedotin have Potential in Lymphomas?

A look at the latest data for a CD79b targeted ADC in lymphomas

January 4, 2017

The future of our cancer research business

A look at the emerging trends we can expect in 2017 for cancer research

January 3, 2017

Seattle Genetics vadastuximab talirine and liver toxicities in AML

An in-depth look at the sudden and unexpected announcement underlying the clinical hold for Seattle Genetics anti-CD33 ADC Vadastuximab Talirine in AML.

December 28, 2016

How the Leukemia Lymphoma Society plans to Beat AML

Tackling heterogeneity in older people with AML using novel targeted therapies.

December 21, 2016

LeonardList showcases 10 Lymphoma Abstracts at ASH16

#LeonardList showcases 10 Lymphoma Abstracts at ASH16

December 19, 2016

Post ASH16 Reader Q+A on CAR T cell therapies

We answer more questions on CAR T cell therapies and ADCs in acute leukemias from ASH

December 16, 2016
The Alamo, San Antonio TX

Emerging Trends from SABCS16 in San Antonio

3 trends from SABCS16 that you may hear more about

December 15, 2016

ASH16 Update on BCMA CAR T cell therapies

A look at the new various developments in CAR Therapies targeting BCMA in multiple myeloma

December 14, 2016
Pedicab at ASH16 in San Diego

Highlights of ASH 2016 Part 2

We answer several critical questions that readers have sent in based on the CAR T cell data at ASH this week.

December 8, 2016
Downtown San Diego during ASH 2016

7 Things I Learned at #ASH16

Highlights (Part 1) from 2016 ASH Annual Meeting in San Diego - 7 initial impressions

December 6, 2016

Gems from the Poster Halls at EORTC-NCI-AACR in Munich

Gems from the Poster Hall on Wednesday at EORTC-NCI-AACR Molecular Targets meeting in Munich

November 30, 2016

Making breast cancer cells become normal again

Can we revert the mutant phenotype in breast cancer and return to a normal, non cancerous phenotype?

November 30, 2016

ENA 2016 Immunotherapy Symposium Highlights

Highlights from the Charles River Immunotherapy Symposium in Munich, 2016

November 29, 2016
ASH15 Late Breaker Session

ASH16 Super Friday Preview

If you have plans to be in San Diego for #ASH16 what should you attend on Friday?

November 28, 2016

Juno plays Russian Roulette with JCAR015

A most unfortunate follow-up to the ongoing safety issues with Juno's JCAR015 and neurotoxicity in the run-up to #ASH16

November 23, 2016

SITC 2016 Can Nektar Boost Checkpoint Performance

Without effector T cells in the tumour, checkpoints won't work. So how do we attract more in? Here's one way to do it...

November 16, 2016

SITC 2016 New Immunotherapy Drug Development

A look at new ways to boost checkpoint therapy performance including agents in development from small biotechs

November 17, 2016

SITC 2016 Update on the Competitive Urothelial Cancer Market

Update on important new data in urothelial cancers and how the landscape is moving quickly

November 15, 2016
National Harbor Maryland

Red Flags in SITC Lirilumab plus Nivolumab Head and Neck Cancer Data

Does adding lirilumab to nivolumab move the needle in relapsed SCCHN?

November 14, 2016

ASH16 Preview on Acute Myeloid Leukemia AML

An in-depth review of what to expect from AML new product development in San Diego

November 11, 2016

ASH16 Preview of CAR T Cell Therapies

What To Watch Out For in CAR T Cell Therapies at ASH in San Diego in December 2016

November 7, 2016

ASH16 Abstracts are out! So What’s Hot at ASH16? My Initial Impressions

Initial impressions of abstracts for ASH16 in San Diego

November 3, 2016

Promising new combos in cancer research pipelines

Four more combination trials of interest in cancer research that may be worth watching out for

November 2, 2016

ESMO16 Gems from the Poster Halls Part 2

Four pretty cool approaches to combination cancer immunotherapy stood out at #ESMO16 in Copenhagen...

November 1, 2016

Glycomics The Third Language of Life

How will glycomics impact cancer research? Some interesting new developments are emerging in this field

October 27, 2016

Insights from biomarkers in ovarian cancer

Can biomarkers help us improve clinical trial outcomes?

October 25, 2016

Where does rucaparib fit in ovarian cancer?

How does the rucaparib data at ESMO fit in the treatment paradigm and what's next for PARPi?

October 24, 2016

What do Myriad Genetics really think of the Niraparib data?

Following the dispute between Tesaro and Myriad on HRD testing, here's Myriad's perspective on the data presented

October 20, 2016

New Directions in Advanced Lung Cancer

Yesterday saw the FDA approval of atezolizumab (Tecentriq) for the second-line treatment of metastatic…

October 19, 2016

ESMO16 Day 3 Daily Digest

Commentary on Sunday at ESMO16 with a focus on the lung cancer data in the Presidential Symposium

October 10, 2016

ESMO16 Day 2 Digest

Commentary on Day 2 at ESMO16

October 8, 2016

What Tesaro aren’t telling you about niraparib

What you need to know about the Tesaro niraparib ovarian cancer data presented at ESMO 2016.

October 8, 2016

ESMO16 Congress Day 1 Digest

Commentary on Day 1 at ESMO 2016 Congress in Copenhagen.

October 7, 2016

How do you calculate Immunoscore? A tour of HalioDx

Audio Slideshow tour of HalioDx lab that shows how digital pathology is used to calculate Immunoscore an immune based colon cancer assay

October 3, 2016

September BSB Reader Mailbag

Latest BSB mailbag covers targeted therapies, immunotherapy and #ESMO16

September 29, 2016

Corvus moves fast to target tumor microenvironment and improve checkpoint responses

Corvus Pharmaceuticals accelerates development of A2A receptor antagonist CPI-444 that could improve checkpoint responses.

September 26, 2016
Dr Eric Pamer presenting at CIML40

Manipulating the Microbiota to Improve Clinical Outcomes. An interview with Eric Pamer

Interview with Dr Eric Pamer on impact of the microbiota on the innate and adaptive immune systems and future directions.

September 28, 2016

Targeting Natural Killer Cells in AML

New research shows potential of cell therapy with allogeneic memory-like natural killer NK cells in AML.

September 27, 2016
Professor Ton Schumacher at CIML40

Is Targeting Neoantigens the Next Frontier in Cancer Immunotherapy?

Interview with Prof Ton Schumacher at scientific meeting to celebrate 40 years of Centre d’Immunologie de Marseille-Luminy (CIML).

September 22, 2016

François Romagné Accelerates Cancer Immunotherapy Innovation in Marseille

Interview with Professor François Romagné, Scientific Director of MI-mAbs, an immuno-oncology drug discovery venture in the Marseille Immunopôle cluster.

September 21, 2016

Innate Pharma at an Inflexion Point: An interview with CEO Hervé Brailly

Interview with Innate Pharma CEO Dr Hervé Brailly on clinical trial readouts expected and his vision for company

September 20, 2016

Why target the Innate Immune system? An interview with Eric Vivier

Professor Eric Vivier is Director of the Centre d’Immunologie de Marseille-Luminy and a co-founder of Innate Pharma and the Marseille Immunopôle. He is a leading researcher in the field of innate immunity.

September 19, 2016

HalioDX CEO Vincent Fert outlines commercial strategy for Immunoscore in US and Europe

Interview with HalioDx CEO Vincent Fert on commercial strategy for Immunoscore diagnostic test.

September 14, 2016

ESMO16 Preview 7 Key Trials in Breast Cancer

A look at some of the key breast cancer abstracts to watch out for at #ESMO16 in Copenhagen

September 14, 2016

ESMO16 Preview Novel Targeted Therapies

Five key approaches in developmental therapeutics in the spotlight at ESMO16

September 13, 2016

What’s Hot in Ovarian Cancer at ESMO16?

A look at 9 key abstracts in ovarian cancer at #ESMO16 and what to expect

September 8, 2016

ESMO16 What’s Hot in Head and Neck Cancer?

What can we expect in Head & Neck cancer at #ESMO16 in Copenhagen?

September 7, 2016

ESMO16 Preview on Late Breaking Abstracts in Lung Cancer

A look at what to expect from the lung cancer late breakers at #ESMO16 - are there any surprises or controversies?

September 6, 2016

ESMO16 Preview 1 Novel Target Data Offers Potential to Overcome Barriers to Cancer Drug Resistance

Overcoming barriers to resistance in epithelial cancers - a look at a novel oncogenic target

September 1, 2016

August Journal Club – Cancer Immunotherapy

Launch of the BSB Journal Club - this inaugural edition explores T cell dysfunction and exhaustion

August 25, 2016

Modelling the Tumour Microenvironment

Interview with Prof Fran Balkwill from Barts Cancer Institute on 3D modelling of the tumor microenvironment in ovarian cancer

August 22, 2016

PsiOxus is a cancer immunotherapy company to watch – Part 2 of an interview with CEO John Beadle

Part 2 of interview with PsiOxus Therapeutics CEO Dr John Beadle discusses corporate strategy and challenges faced by an emerging biotech company.

August 17, 2016

Can PsiOxus become a world leading immuno-oncolytic virus company?

An innovative and promising approach to cancer immunotherapy using adenoviruses to deliver multiple warheads to tumours

August 16, 2016

Beyond T-VEC – a look at oncolytic viral immunotherapy

A primer on the oncolytics viral therapy landscape - beyond T-VEC

August 15, 2016

Can neoantigen vaccines make a difference in cancer research?

This is the second in our mini-series on neoantigens and looks at whether neoantigen based cancer vaccines can make a difference in the treatment of solid tumors.

August 10, 2016

NEON shines the light on Neoantigen targeted Cancer Immunotherapy

Cary Pfeffer of Third Rock Ventures describes how a novel neoantigen vaccine in academia transitioned into a commercial company with exciting prospects...

August 11, 2016

What are neoantigens and why do they matter in cancer immunotherapy?

A primer on neoantigens and their importance in cancer research

August 9, 2016

Detailed thoughts on BMS CheckMate–026 1L trial in NSCLC

The BMS CheckMate-026 trial in 1L NSCLC did not meet it's primary endpoint. What can we learn from the failure?

August 5, 2016

New developments in allogeneic cellular therapies

Collaborations in the adoptive cell therapy space have now branched out from autologous to allogeneic products. What's the skinny?

August 5, 2016

What’s new on emerging resistance to cancer immunotherapy?

What factors contribute to resistance with checkpoint blockade and how can this be overcome?

August 4, 2016

Biotech Mailbag – Jounce & the CAR T Race to Market

July Reader Q&A - thoughts on Jounce, Celgene, BMS, J&J and CAR T cell therapies...

July 27, 2016

Can we safely revisit the IGF pathway with combinations?

Lilly and Boehringer Ingelheim have announced a clinical trial collaboration in metastatic breast cancer with the CDK4/6 inhibitor, abemaciclib, and the IGF antibody, BI 836845.

July 14, 2016

The changing face of the SCCHN landscape

A example of how different targeted therapy and immunotherapy combinations could be both useful and different from what we've seen before

July 12, 2016

JUNO setback by Patient Deaths due to CAR T Cell Neurotoxicity

Juno ROCKET trial put on clinical hold following 3 death due to cerebral edema. What's the skinny?

July 7, 2016

Can epigenetics play a role in immunomodulation?

Will priming the tumour microenvironment with epigenetic therapies such as HDACs lead to enhanced activity with subsequent immunotherapy?

July 7, 2016

One Step Beyond

With so many new anti-cancer agents, including immunotherapies, emerging in company pipelines, this means that we could see the evolution of important therapy sequences... going beyond combinations.

July 5, 2016

The impact of niraparib on the ovarian cancer landscape

How will niraparib impact the ovarian cancer market?

June 30, 2016

Xencor and Novartis storm the hematologic bispecific market

The oncology bispecific market is heating up with J&J collaborating with Macrogenics and Novartis with Xencor. We discuss the skinny...

June 28, 2016

The potential downside of cancer immunotherapy

We've seen some wonderful responses with checkpoint blockade and cancer immunotherapies, but there are some downsides that need to be considered.

June 27, 2016

How to turn a cold tumour into a hot one

Can we turn a cold tumour into a hot one where some patients can respond to therapy?

June 23, 2016

Checkpoint blockade in MSI High cancers

Update on ASCO checkpoint blockade data for colorectal and other MSI-High cancers

June 22, 2016

Immunoscore validated as an important biomarker for colon cancer

An easy to use new biomarker emerges to help oncologists select colon cancer patients for cancer immunotherapies.

June 20, 2016

Reader Mailbag – TCR T cell Gene Editing in Multiple Myeloma

Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?

June 17, 2016

Beyond PD-L1 Immunotherapy Biomarkers

Can we find and use several biomarkers to triangulate responders and non-responders?

June 16, 2016

Urothelial Cancer Immunotherapy is a Competitive Landscape

A look at the increasingly competitive metastatic urothelial carcinoma landscape

June 15, 2016

Contemplations on ASCO Lung Cancer Data with Dr Stephen Liu

What to make of the various combination trials presented at ASCO 2016?

June 13, 2016

5 Important and Emerging Trends from ASCO 2016

A number of points of strategic importance fell out of the ASCO data dump. What are they and why do they matter?

June 9, 2016

ASCO 2016 Monday Blog #ASCO16

Commentary from Monday at ASCO 2016 American Society of Clinical Oncology annual meeting in Chicago

June 6, 2016

BMS Ipilimumab prostate cancer immunotherapy trial fails but where is the data?

Prior to chemotherapy men with advanced prostate cancer did not live longer if they received ipilimumab compared to just receiving placebo. The phase 3 trial was a failure.

June 5, 2016

ASCO 2016 Sunday Blog #ASCO16

Top-line commentary from Sunday at ASCO 2016 annual meeting.

June 5, 2016
Chicago River

ASCO 2016 Chicago Saturday Blog #ASCO16

Top-line commentary from Saturday at ASCO 2016 annual meeting.

June 4, 2016

ASCO 2016 – Top 10 Immunotherapy Abstracts Worth Checking Out

What are our Top Ten immunotherapy abstracts of note at ASCO 2016?

June 2, 2016

ASCO 2016 Preview on Targeted Therapies

The poster childs for targeted therapies have been surprising - CML and lung cancer -- what's new here at #ASCO16?

June 1, 2016

The BET Bromodomain Landscape in Cancer Research

The bromodomain market has exploded in recent years with many more agents in the development. Are they all the same though?

May 26, 2016

What we learnt at AACR about Aduro ADU-S100

Can we safely combine a STING agonist with a checkpoint inhibitor to generate more effectiveness in melanoma and lymphomas? We asked experts at AACR what they really thought...

May 25, 2016

Gems from the AACR Poster Hall – Part 2

A look at Bayer's early oncology pipeline and a curious new class called MNK (Mink) inhibitors

May 24, 2016

Statistical Challenges of Immunotherapy Clinical Trial Design

What can we learn about clinical trial design from immunotherapy combinations?

May 23, 2016

Drug Discovery Targets Cancer Vulnerabilities

Commentary from the AACR Precision Medicine Conference in Miami on Targeting the Vulnerabilities of Cancer.

May 20, 2016

George Coukos Drives Novel Ovarian Cancer Immunotherapies Forward

How can we improve T cell trafficking in ovarian cancer? Professor Coukos highlights numerous ways this could be achieved!

May 16, 2016

Gems from the Poster Hall at AACR16 – Part 1

A look at small biotechs producing quality preclinical data at #AACR16 that may lead to clinical development in the near future

May 12, 2016

Is APRIL an exciting new target in Multiple Myeloma?

A look at the BCMA/APRIL landscape in multiple myeloma - this is rapidly becoming a competitive target

May 11, 2016

Targeting OX40 in advanced cancers – Part 2

Beyond checkpoint blockade, companies are now exploring what happens when you combine them with immune agonists such as OX40. Here we explore an industry perspective.

May 10, 2016

AACR Cancer Immunotherapy Insights from Dr Bernard Fox

A wide ranging discussion about how to light the fires in non-immunogenic or cold tumours - OX40, STING, vaccines and more discussed!

May 9, 2016

Can chemotherapy improve checkpoint blockade in advanced colorectal cancer?

Can we safely and effectively add a checkpoint inhibitor to standard chemotherapy and VEGF inhibition? Early proof of concept in patients with metastatic colorectal cancer.

May 4, 2016

Breaking the Immunology Rules – an interview with Dr Michel Sadelain on how CAR T cell therapy will crack solid tumors

At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.

May 5, 2016

Controversy: Is Chemotherapy Immunotherapy?

Chemotherapy can have a potentiating effect on cancer immunotherapy. The positive effects may surprise some readers...

May 3, 2016

7 Significant Things I Learned at AACR16 That You Don’t Want to Ignore

What were the major learning points from AACR that will make an impact over the next 1-2 years? Chhhhanges are afoot...

May 2, 2016

Thunderbirds are GO!

Season 2 of the Novel Targets has launched, plus the eagerly awaited April Readers Q&A Mailbag

April 29, 2016

Can ADCs be adapted to tackling MRSA?

Can we use technological approaches from oncology to applying creative ways to treating bacterial infections?

April 27, 2016

AACR 2016 New Orleans Day 4 Blog

Commentary on Tuesday sessions at AACR 2016 annual meeting

April 19, 2016

AACR 2016 New Orleans Day 3 Blog

Commentary on Monday at AACR 2016 annual meeting

April 18, 2016

AACR 2016 New Orleans Day 2 Blog

Commentary from Sunday at 2016 AACR annual meeting

April 17, 2016

AACR 2016 New Orleans Day 1 Blog

Commentary on Day 1 of AACR 2016 annual meeting in New Orleans.

April 16, 2016

What next for Bcl2 inhibitors after venetoclax’s approval in CLL?

Where next for Bcl2 inhibitors beyond CLL and Del17p? Which novel combinations might be an attractive strategy?

April 13, 2016

Osimertinib front-line data wows European Lung 2016

First-line data for AstraZeneca’s ($AZN) third generation EGFR inhibitor osimertinib (Tagrisso) impresses at the 2016 European Lung Cancer Conference in Geneva.

April 14, 2016

AACR 2016 CD40 Cancer Immunotherapy

In this preview of AACR 2016, we're looking at the CD40 landscape, some of the new companies that have entered the scene and what presentations to look out for at AACR 2016 (and why they matter).

April 8, 2016

OX40 immune agonists at AACR 2016

Today post is on OX40 (CD134) as a novel immuno-target and what the OX40 cancer immunotherapy landscape looks like.

April 7, 2016

AACR 2016 GITR Cancer Immunotherapy

There are now several agonist antibodies in development and entering the clinic that seek to activate GITR, and new data is expected at AACR 2016.

April 6, 2016

AACR 2016 Cancer Immunotherapy Targeting IDO1 TDO

This post looks at some of the data at AACR 2016 for cancer immunotherapies that target IDO1 and TDO and their downstream effectors.

April 5, 2016

Targeting Acquired Resistance in Prostate Cancer

The discovery of a novel target in castration-resistant prostate cancer offers the potential to overcome or delay acquired resistance to enzalutamide.

April 4, 2016

AACR 2016 A Preview of anti TIM-3 and LAG-3 Checkpoints

A look at alternative checkpoint inhibitors, anti-TIM-3 and LAG-3 compounds in early development at AACR

April 1, 2016

Beyond Blinatumomab – Update on Bispecific T cell Engagers

In this post I've taken a close look at one cancer immunotherapy approach with a lot of data at AACR - bispecific T cell engagers.

March 31, 2016

Future of Cancer Immunotherapy

Commentary on some of the latest cancer immunotherapy papers

March 29, 2016

Biotech Strategy Blog Mailbag Monday

Subscriber questions on recent immuno-oncology, Genentech, Kite Pharma and Gilead company news

March 21, 2016

Top 10 Abstracts at AACR 2016

Pick of 10 abstracts at AACR 2016 annual meeting in New Orleans that may answer critical cancer research questions

March 17, 2016

What’s Hot at AACR 2016? Annual Meeting Preview 1

Cancer Immunotherapy dominates AACR 2016 annual meeting in New Orleans.

March 16, 2016

Making CAR T cell therapy more effective in leukemia and solid tumors

Finding new ways to optimise CAR T cell therapy in CLL and solid tumours may be closer than you think...

March 15, 2016

Gems from the EBCC10 Poster Hall

Review of 4 noteworthy posters at the 2016 European Breast Cancer Conference in Amsterdam organised by European Cancer Organisation ECCO

March 10, 2016

Trends in Haplo transplants impact Bellicum

Trends in Haplo stem cell transplants may impact Bellicum Pharmaceuticals adjunct T Cell therapy BPX–501

March 9, 2016

Is TIM–3 the next important checkpoint target?

Could immune resistance be reversed or prevented by the addition of appropriate checkpoint blockade? Which ones matter though, that is the critical question?

March 3, 2016

Could a Novel Cell Therapy replace CAR T Cell Therapy?

Interview at BMT Tandem 2016 about a novel cell therapy that could compete with or replace CAR T cell therapy

March 1, 2016

Are checkpoints playing with fire?

Commentary on presentation by Dr Philippe Armand at BMT Tandem meeting on “Checkpoint Blockade in SCT, Data & Hope, Promise & Peril”

February 25, 2016

Optimizing CD19 CAR T Cell Therapy

Interview with Dr Michael Jensen on CD19 CAR T Cell Therapy

February 23, 2016

Challenges and Opportunities of CAR T Cell Therapy in CLL

Interview at BMT Tandem 2016 with Dr David Porter U Penn on CD19 targeted CAR T cell therapy in CLL

February 19, 2016

What’s hot at BMT Tandem 2016 in Honolulu?

Preview of noteworthy sessions at 2016 BMT Tandem meeting in Honolulu, Hawaii

February 17, 2016

The Next Big Wave in Multiple Myeloma

How do we decide how to incorporate the newly approved drugs in Multiple Myeloma and what's the next wave of therapies we can expect to see evolve?

February 11, 2016

What’s driving the GvHD Landscape? #BMTTandem16

What are some of the strategic trends and drivers in the Graft versus Host Disease (GvHD) space at #BMTTandem16?

February 9, 2016

Will Unum’s approach take the CAR T cell therapy market by storm?

Unum have developed a completely different approach to traditional CAR T cell therapies. Will they make an impact in patients?

February 4, 2016

Immunotherapy for Lymphoma using T cells Targeting Multiple Tumor-Associated Antigens

A novel cell therapy approach uses T cells targeting multiple tumor-associated antigens.

February 3, 2016

Update on Targeted therapies and Immunotherapies in Gastric Cancer

Who will move the needle in gastric and oesophageal cancers - targeted therapies or checkpoint immunoherapies?

January 27, 2016

Will pembrolizumab extend its activity in GI cancers?

Will checkpoint blockade be effective in multiple GI cancers and if so, why?

January 25, 2016

Why didn’t Ipilimumab plus Chemo work in Metastatic Urothelial Cancer?

A trial of gemcitabine plus cisplatin plus ipilimumab in patients with metastatic urothelial cancer failed to meet it's primary endpoint.

January 22, 2016

Potential of a Novel Non-Invasive Liquid Biopsy Prostate Cancer Biomarker

A novel non-invasive liquid biopsy may offer a potential novel biomarker that will help in sequencing prostate cancer drugs.

January 21, 2016

New combinations and targets in advanced prostate cancer

How do we overcome resistance to Zytiga? There are some encouraging developments in this area to report.

January 20, 2016

A New Race to Market in Advanced Prostate Cancer

Two biotech companies are in a race to market for a novel target in advanced prostate cancer.

January 19, 2016

Day 3 Highlights from JP Morgan Healthcare Conference #JPM16

Commentary on Wednesday corporate presentations at 2016 JP Morgan Healthcare conference in San Francisco

January 13, 2016

Highlights of #JPM16 Healthcare Conference Day 2

Commentary on some of the presentations at Day 2 of JP Morgan Healthcare conference in San Francisco.

January 12, 2016

Highlights of #JPM16 Healthcare Conference Day 1

Commentary around some of the corporate presentations at Day 1 of the 2016 JP Morgan Healthcare conference in San Francisco.

January 11, 2016

Is Ocular Toxicity a big deal with Denintuzumab Mafodotin SGN-CD19A? #JPM16

An interview with Seattle Genetics CEO, Dr Clay Siegall on CD19A ocular toxicity and the competition from checkpoint inhibitors in Hodgkin's lymphoma.

January 11, 2016

Midostaurin in AML – Better Late than Never!

An in-depth look at the FLT3 inhibitor midostaurin and its potential impact on the treatment for AML.

January 6, 2016

New Horizons in CLL Treatment

ASH 2015 interview with Dr Ian Flinn, Director of the Blood Cancer Research Program at the Sarah Cannon Research Institute.

January 5, 2016
ASH15 Late Breaker Session

New Treatments for CLL with Deletions in 17p

A look at the new CLL 17p deletion data at ASH in the late breaker session

January 4, 2016

Understanding the Cellectis UCART19 Case Report – Part 2 of an Interview with Prof Waseem Qasim

Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.

December 16, 2015

Potential of Gene Editing – Part 1 of Interview with Prof Waseem Qasim

Part 1 of an interview with Prof Waseem Qasim.

December 15, 2015

Promising new agents in development for breast cancer

Five promising new agents in development for the treatment of ER+ or HER2+ or triple negative breast cancer emerge from #SABCS15

December 14, 2015

Checkpoint therapy update in metastatic breast cancer

Adding chemotherapy or an ADC boosts the immunogenic effects prior to checkpoint therapy in metastatic breast cancers

December 11, 2015

Manic Monday at ASH 2015

Commentary on "Manic Monday" at ASH 2015

December 7, 2015

Highlights from Plenary Sunday at #ASH15

Commentary on Plenary Sunday at the 2015 ASH annual meeting in Orlando.

December 6, 2015

Highlights from Saturday at ASH 2015 Annual Meeting #ASH15

Commentary on Saturday at ASH15

December 5, 2015

ASH 2015 Preview: will venetoclax fall or rise?

In the last of our American Society of Hematology (ASH) 2015 annual meeting previews, we take a broad…

December 2, 2015

ASH15 Preview on Aggressive Lymphomas

There are an encouraging number of promising therapies in development for Aggressive Lymphomas at ASH this year - which ones should you watch out for?

December 1, 2015

ASH15 Multiple Myeloma Preview

With four new approvals in multiple myeloma in 2015, ASH is expected to have a surfeit of riches to review for this disease...

November 30, 2015

Future of Cancer Immunotherapy Biomarkers

Where is the field of immune biomarkers going beyond PD-L1 in the next few years?

November 27, 2015

ASH15 Preview Checkpoints in classical Hodgkin Lymphoma

Checkpoints in classical Hodgkins Lymphoma - how is the data holding up one year on?

November 25, 2015

Exploring the Potential of Therapeutic Cancer Vaccines

At the recent Society for Immunotherapy of Cancer (SITC) annual meeting, Dr Chris Heery presented a poster on the results of a phase 1 clinical trial to evaluate the safety and tolerability of a therapeutic vaccine targeting brachyury.

November 23, 2015

Why do some FLT3 inhibitors work in AML and some don’t?

A look at the FLT3 AML landscape - what's new?

November 19, 2015

Q&A on hot topics in CAR T cell therapies

Our latest Q&A based on reader questions - In the Hot Spot: On CAR T cell therapies

November 18, 2015

Preview of ASH15 Late Breaking Abstracts

Preview of some of the late-breaking abstracts at the 2015 annual meeting of the American Society of Hematology ASH15 in Orlando.

November 16, 2015

Novel Immunotherapies and Combinations

Interview with Dr Mario Sznol on Novel Immunotherapies and Combinations

November 17, 2015

Gut Bacteria Impact Checkpoint Inhibitor efficacy

Dr Tom Gajewski (University of Chicago) talks about work from his lab that shows the gut microbiota can impact the efficacy of checkpoint inhibitors.

November 16, 2015

AstraZeneca’s AZD9291 osimertinib is approved as Tagrisso

AstraZeneca's AZD9291 was approved by the FDA in EGFR T90M mutation positive lung cancer today and is now known as osimertinib or Tagrisso.

November 13, 2015

Strategies to overcome CAR T cell therapy resistance

Interview with a leading expert on strategies to overcome CAR T Cell Therapy Resistance

November 12, 2015

How long do we need to give a checkpoint inhibitor for?

At SITC 2015, we heard a tremendous amount of data, but a fresh controversy emerged regarding checkpoint inhibition...

November 11, 2015

Do Cellectis CAR T Cells Really Work?

Expert opinion on First Clinical Application of TALEN Engineered Universal CAR19 T Cells in B-ALL

November 10, 2015

Mixed results with Macrogenics enoblituzumab at SITC

Enoblituzumab is an immune stimulant that targets B7-H3 leading to more T cells.

November 7, 2015

Did the epacadostat combo data disappoint at SITC?

Is Incyte's epacadostat (IDO1 inhibitor) ready for prime time?

November 7, 2015

SITC 2015 – what did we learn from the cancer immunotherapy workshops?

Review of the highlights from the SITC 2015 pre-meeting workshops

November 5, 2015

What IS Hot at ASH 2015 in Orlando? #ASH15 abstracts – Preview 1

Most of the abstracts for the 2015 annual meeting of the American Society of Hematology (ASH) have just gone online. This is a quick initial preview of a few that caught my attention in the immunotherapy space.

November 5, 2015

SITC 2015 International Cancer Immunotherapy Symposium

Commentary on the International Cancer Immunotherapy Symposium held at SITC 2015

November 4, 2015

Preview of SITC 2015 Cancer Immunotherapy Meeting

Preview of what's hot at the 2015 Society for Immunotherapy of Cancer (SITC) annual meeting at National Harbor, MD.

November 3, 2015

CD40 as a Cancer Immunotherapy Target

Companies in the ImmunoOncology space are looking at ways to improve responses with checkpoint inhibitors. Adding an immune agonist is one way to do this.

November 3, 2015

How do we boost the effectiveness of checkpoint inhibitors?

A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.

November 2, 2015

Immunosurveillance, Immunoscore & Personalized Cancer Immunotherapy – an interview with Jérôme Galon

Interview with Dr Jérôme Galon on Immunosurveillance, Immunoscore and Personalized Cancer Immunotherapy.

October 30, 2015

What’s Hot at AACR #Targets15 in Boston?

Preview of the key topics coming up at the AACR-NCI-EORTC Molecular Targets meeting in Boston, including Pasi Janne's interesting data on T790M negative NSCLC...

October 27, 2015

Is there a biomarker for cetuximab in colon cancer?

Finding a biomarker for EGFR monoclonal antibodies in colon cancer has proven elusive but things may be a-changin'...

October 22, 2015

Why combine radiation with cancer immunotherapy?

Radiation has the potential to generate an immune response that may lead to an abscopal effect when combined with a checkpoint inhibitor.

October 21, 2015

New oncology targets emerge from ECC 2015 – Part 1

Some promising new clinical targets emerged at ECC in Vienna, including DLL3 in SCLC, TRK gene rearrangements, Notch3 and PTK7. What did we think of the data and what issues should you look out for?

October 19, 2015

Is Combining a checkpoint plus an EGFR inhibitor a risky combination?

Will an increase in ILD cases scupper the AZD9291 plus durvalumab combination study in lung cancer? Will there be an advantage for Clovis or not?

October 13, 2015

Is ocrelizumab a game changer in MS?

At the 2015 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting Barcelona on Friday, Dr Stephen Hauser (UCSF) presented the data for octrelizumab, an anti-CD20 monoclonal antibody, on behalf of the investigators in the OPERA trial.

October 11, 2015

Controversies in lung cancer immunotherapy

Should we be using the PDL1 antibody assay to screen patients for therapy with anti-PD1 and PD-L1 checkpoint inhibitors or? How useful is the test? The debate is heating up!

October 26, 2015

Where are the breakthroughs coming in Soft Tissue Sarcoma?

Interview at ECC 2015 with Dr George Demetri on new developments in Soft Tissue Sarcoma

October 6, 2015

Potential of Checkpoint Inhibitors in Ovarian Cancer

Interview with Dr Nora Disis about the phase 1b trial results for avelumab in ovarian cancer and the challenges of developing these agents in non-hypermutated tumour types

October 5, 2015

What’s hot at Day 3 of European Cancer Congress?

Commentary on Day 3 of the European Cancer Congress in Vienna

September 28, 2015

ECC Day 2 Highlights – Checkpoints in Lung and Bladder Cancer

Commentary on Day 2 of the European Cancer Congress in Vienna

September 27, 2015

ECC Day 1 Highlights – the battle for Advanced Renal Cell Carcinoma

Highlights from Day 1 of the ECC 2015 (ECCO) meeting in Vienna

September 25, 2015

Novel Targets Podcast 6 – Immune Agonists

What happens when we literally step on the gas with immune agonists?

September 24, 2015

Checkpoint inhibition: targeting TIM-3

T cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) is widely expressed on immune cells. What's the potential for a TIM-3 checkpoint inhibitor?

September 17, 2015

What’s hot at the AACR International Cancer Immunotherapy Conference?

Review of noteworthy abstracts at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York

September 16, 2015
Dr Holbrook Kohrt

Holbrook Kohrt Leads the Way in Targeting CD137

Holbrook Kohrt is a Stanford medical oncologist and clinical researcher who is leading the way in cancer immunotherapy combination strategies targeting CD137 (4-1BB).

September 15, 2015

Immunocore ImmTAC TCR platform offers combination promise

Immunocore is an immuno-oncology company with an innovative approach to targeting T Cell Receptors (TCR) using their proprietary ImmTAC (Immune mobilising monoclonal TCRs against cancer) technology platform.

September 14, 2015

ECC Vienna Preview 2 Oral Presentations

What's hot at ECCO 2015 in the oral sessions? An in-depth preview of what we can expect to hear about in Vienna...

September 10, 2015

ECC Vienna Preview 1 Late Breaking Abstracts

What's hot in the 2015 ECCO late breaking abstracts in Vienna? Find out here...

September 8, 2015

Atezolizumab PDL1 Checkpoint Inhibitor will change Bladder Cancer Treatment

Atezolizumab is expected to change the standard of care for the treatment of metastatic urothelial bladder cancer

September 3, 2015

The value of BRAF targeted cancer therapies in lung and colorectal cancer

The role of basket trials in small cancer subsets will be important to defining what targeted therapies work well...

August 20, 2015

Adoptive Cell Therapies – an interview with Dr Carl June

Dr Carl June on progress of CAR T cell therapies in CLL, myeloma and solid tumours

August 14, 2015

Adoptive Cell Therapy: An Interview with Dr Steven Rosenberg

We know that TILs can be effective in advanced melanoma, but what about common epithelial solid tumours? Can it work in these cancers too? Find out from Dr Rosenberg's latest work what's happening...

August 12, 2015

Oncolytic viruses – are they ready for prime time?

Oncolytic viruses are fast becoming a hot new area in cancer research but who are the players and where is this field going?

August 6, 2015

Will targeting NY-ESO-1 prime the immune system in cancer?

Exploring NY-ESO-1 as a valid target in sarcoma, multiple myeloma and metastatic melanoma...

August 3, 2015

Will venetoclax impact acute lymphocytic leukemia?

Some interesting potential new therapeutic approaches on the horizon in pediatric ALL - beyond CAR T cell therapies lie Bcl2 inhibitors

July 27, 2015

BMS and Exelixis announce new renal cell cancer data

Will checkpoint inhibitors make their mark in renal cell carcinoma and how will they be integrated into a treatment paradigm dominated by VEGF inhibitors?

July 22, 2015

Novel Targets Podcast: Non-inflamed Tumours

Can we find new ways to target prostate cancer and other non-immunogenic tumours with immunotherapies? The answer may surprise...

July 21, 2015

Biotech Strategy questions answered on BRAF, MEK, immunotherapy, mirvetuximab soravtansine and venetoclax

This month's Biotech Strategy Blog mail bag.

July 17, 2015

AstraZeneca take a punt on immuno-oncology

Interview with Dr Rob Iannone of AstraZeneca on their IO pipeline

July 15, 2015

Update on resistance and transformation in lung cancer

As we learn more about mechanisms of resistance in ALK+ and T790M mutated lung cancer, combination strategies are likely to evolve - but which ones?

July 9, 2015

Has AZD9291 been filed for T790M+ lung cancer?

Clovis have started their rolling NDA for rociletinib in T790M-positive lung cancer - what about AstraZeneca's AZD9291?

July 6, 2015
Dr William Pao Roche

Do you need a CAR T Cell Therapy to be a Global Cancer Immunotherapy Company?

Interview with Dr William Pao on the Roche antibody based cancer immunotherapy strategy.

July 1, 2015

Juno and Celgene’s unexpected CAR-T cell and TCR collaboration

Editas presented some elegant work using their gene editing technology with CRISPR/Cas9 to modify T cells at ASGCT. Who would have guessed a short time afterwards Juno and Celgene would sign a 10 year collaboration?

June 30, 2015

Future of Prostate Cancer Immunotherapy

ASCO 2015 interview with Dr James Gulley from NCI on Prostate Cancer Immunotherapy.

June 29, 2015

ASCO 2015 Review of New Developments in Sarcoma

What's hot in soft tissue sarcomas at ASCO 2015? Find out more...

June 22, 2015

Biotech Strategy questions answered on neratinib, bavituximab, enzalutamide and more!

Insights on targeted therapies from ASCO - questions from subs on neratinib, bavituximab, enzalutamide, Gilead's pipeline and MDSCs...

June 17, 2015

Checkpoint inhibitors show early promise in Small Cell Lung Cancer

We've heard a lot about checkpoint immunotherapies in non-small cell lung cancer (NSCLC), but what about it's deadlier cousin, small cell lung cancer (SCLC)? Find out more...

June 16, 2015

Beyond the Big Four in checkpoint blockade

Beyond the Big Four in checkpoint inhibitors, there is a raft of other companies anxious to get in the action. We take a look at Merck Serono and their progress with avelumab, an anti-PDL1 antibody

June 11, 2015

Combined checkpoint inhibition and chemotherapy – useful or not?

How do we help patients who are non-responders or have stable disease respond to checkpoint inhibitors? Will chemotherapy combos help or not?

June 8, 2015

Highlights of Day 4 at ASCO 2015 Annual Meeting

Highlights from Monday at the 2015 ASCO annual meeting in Chicago

June 1, 2015

ASCO 2015 Highlights of Day 3

What's hot on Plenary Sunday at ASCO 2015? We'll be updating this blog post during the day.

May 31, 2015

Highlights of ASCO 2015 Day 2 Live Blog

Highlights from Day 2 at ASCO 15 in Chicago

May 30, 2015

ASCO 2015 Cancer Immunotherapy – Reflections on Day 1

Reflections on data presented in the first cancer immunotherapy press briefing at ASCO 2015

May 30, 2015

Suicide Genes – what are they and are they really needed?

Do you need to incorporate a suicide suicide switch into CAR T cells that allows you to turn off the response, force the T cells to self-destruct?

May 28, 2015

Targeting MYC – the undruggable protein – or is it?

Targeting MYC and bromodomains is an emerging area of research as we learn more about super enhancer transcription factor clusters around oncogenes that drive cancer.

May 26, 2015

New therapies for multiple myeloma may make an impact

Data at ASGCT and ASCO highlight potential new treatments in development for multiple myeloma

May 18, 2015

Enzalutamide blows Bicalutamide out of the water in STRIVE trial at AUA15

At AUA 2015 in New Orleans, Dr Celestia Higano (Seattle) presented the results of the STRIVE clinical trial.

May 17, 2015

AUA 2015 Update on bladder cancer

Update on checkpoint inhibitors in urothelial bladder cancer from AUA 2015 and what's in store for new developments with this disease.

May 15, 2015

Highlights of ASCO15 Abstracts – Preview No 1

First in a series of previews of ASCO 2015 annual meeting abstracts.

May 13, 2015

Tom Gajewski takes the STING out of Cancer

Dr Tom Gajewski is working on STING agonists that may have a major role to play in cancer immunotherapy.

May 13, 2015

Promise of Cancer Immunotherapy highlighted at Immunology 2015

At the 2015 annual meeting of the American Association of Immunologists (AAI) in New Orleans, leading experts shared their insights on the “Promise of Cancer Immunotherapy."

May 11, 2015

Top 10 immunotherapy studies with checkpoint blockade at ASCO 2015

What are the hot checkpoint studies to watch out for at ASCO 2015? We created a cheat sheet to follow and track the data as tsunami hits...

May 8, 2015

What happens when you combine checkpoint blockade with an immune stimulant in cancer?

What happens when we combine a checkpoint with an immune stimulant in advanced melanoma?

May 6, 2015

AACR Gems from the Poster Halls in ImmunoOncology

Beyond monotherapy with checkpoint inhibition, what combinations or sequences might be useful to explore next?

April 28, 2015

Are targeted therapies now a thing of the past in the immunotherapy era?

New developments in T790M and ALK lung cancer plus a look at antibodies targeting ADAM17 in head & neck cancer.

April 27, 2015

Where are checkpoint inhibitors going next?

Beyond lung cancer and melanoma, what other tumour types represent the low hanging fruit for checkpoint monotherapy?

April 24, 2015

Is this the end of ipilimumab in melanoma?

As the anti-PD-1 blockers show superiority in front-line metastatic melanoma, is this the end for Yervoy?

April 23, 2015

Top 10 Highlights of AACR 2015

The annual meeting of the American Association for Cancer Research ended today. Find out what were our top 10 highlights.

April 22, 2015

Checkpoint Inhibitor Data Rocks AACR 2015

Checkpoint Inhibitor data is a hot topic at AACR 2015. Data showed they may work in TNBC and also two checkpoints are better than one.

April 21, 2015

Reflections on AACR 2015 Cancer Immunotherapy Data

Cancer Immunotherapy is one of the hot topics at the 2015 AACR annual meeting in Philadelphia.

April 20, 2015

AZD9291 EGFR T790M NSCLC data at European Lung shows longer PFS

Updated data for the AURA phase 1 trial of AZD9291 was presented at the European Lung Cancer Conference in Geneva.

April 17, 2015

Anti-CTLA4 blockade with ipilimumab may be effective in hematologic malignancies

Does checkpoint blockade with CTLA4 have a role to play in hematologic malignancies?

April 15, 2015

UCL Drives CD19 CAR T Cell Therapy Forward in Europe

University College London (UCL) is leading the way in European clinical trials of CAR T Cell therapies that target CD19.

April 14, 2015

Novel Combination Approaches with Checkpoint Inhibitors

Emerging data on different combinations with checkpoint inhibitors suggests that this may increase response rates and outcomes for cancer patients. Find out more...

March 31, 2015

What is STING and why does it matter in cancer immunotherapy?

Novartis have announced a deal with Aduro Biotech for access to their STING-targeted CDN platform technology.

March 30, 2015

How do we improve responses to checkpoint inhibitors in lung cancer?

The mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

March 26, 2015

Will CAR-T cells make an impact in solid tumours?

Novel targets are emerging in urothelial bladder cancer which may offer new therapeutic options for antibody and CAR-T cell therapy development.

March 25, 2015

EAU 2015 Update on enzalutamide PREVAIL trial in advanced prostate cancer

Update in the PREVAIL trial in chemotherapy naive castrate resistant prostate cancer based on 765 deaths from the 2015 EAU conference in Madrid.

March 24, 2015

Impact of TERRAIN trial on European Prostate Cancer treatment landscape #EAU15

The results of the TERRAIN prostate cancer clinical trial data were presented at the 2015 European Association of Urology (EAU) Congress in Madrid today.

March 24, 2015

What would Charles Darwin make of renal cell carcinoma?

Why is renal cell carcinoma so challenging from a clinical and sequencing perspective?

March 23, 2015

Cellular therapy with EBV-CTL reduces death post stem cell transplant

What is the potential of a new cell therapy with cytotoxic T lymphocytes against Epstein Barr Virus (EBV-CTL)?

March 20, 2015

Emerging new biomarker for predicting checkpoint inhibitor responders

Predictive biomarkers of response will be key to reimbursement of immunotherapies in Europe. One is potentially emerging for ipilimumab (Yervoy), which may be useful in speeding up access.

March 19, 2015

AACR 2015 Cancer Immunotherapy Preview

What are the emerging new trends in cancer immunotherapy? Beyond monotherapy lies many combination opportunities yet to be explored. At AACR in April, we will see a raft of novel approaches being discussed.

March 11, 2015

How to enhance checkpoint inhibitors in hematologic malignancies

Will checkpoint inhibitors make an impact in hematologic malignancies or will novel combinations be needed?

March 4, 2015

How to make non-immunogenic cancers sensitive to checkpoint inhibitors

Not all cancers respond to checkpoint inhibitors - how can we change that situation? Here's one example, using prostate cancer as a model...

March 2, 2015

ASCO GU 2015 Preview

What's hot at ASCU GU 2015? Focus on prostate and bladder cancers with checkpoint inhibitors and sequencing therapies

February 26, 2015

CAR-T and Gene Therapy excite BMT Tandem Meeting

Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.

February 25, 2015

Is AR-V7 a useful predictive biomarker in advanced prostate cancer

The ongoing story of the AR-V7 splice variant as a potential biomarker of response in mCRPC

February 23, 2015

Overcoming acquired resistance to EGFR therapies in colorectal cancer

Which new combinations could improve outcomes for colon cancer patients receiving EGFR therapies by overcoming acquired resistance?

February 19, 2015

Molecular Characterisation of Colorectal Cancer

We've seen very little real progress in colorectal cancer beyond incremental improvements since Erbitux and Avastin were approved a decade ago. Are we on the threshold of a new paradigm shift?

February 17, 2015

Overcoming acquired resistance to BRAF in colorectal cancer

Patients with BRAF driven colon cancer don't do as well as those with melanoma: how can we overcome acquired resistance to RAF treatment?

February 13, 2015

CAR-T Cell Therapies from China are a Competitive Threat

Cellular Biomedicine Group (NASDAQ: CBMG) has acquired rights to the Chimeric Antigen Receptor T cell (CAR-T) therapy of the PLA General Hospital in Beijing.

February 11, 2015

The application of TILs, CARs and TCRs in cancer research

What does the evolving landscape for CAR, TIL and TCR cell therapies look like?

February 10, 2015

Tumour infiltrating lymphocytes TILs: what are they and why do they matter?

The NCI have been at the forefront of developing novel cancer immunotherapies for several decades, but what is the current status of their groundbreaking work? Find out more in this primer on TILs.

February 5, 2015

Will venetoclax impact in hematologic malignancies

ABT-199 is now known as venetoclax - has it overcome it's checkered history to get back on track?

February 4, 2015

Potential of Rociletinib in T790M negative NSCLC

Clovis have observed responses in T790M positive AND negative lung cancer with rociletinib - implications for the commercial opportunity are discussed in this post.

January 28, 2015

Enzalutamide beats bicalutamide in advanced prostate cancer

The Phase 2 TERRAIN trial met its primary endpoint (PFS) with enzalutamide beating out bicalutamide in castrate resistant prostate cancer. What next?

January 22, 2015
View of Cambridge and Charles River

Yumanity hopes to impact humanity – an interview with Dr Susan Lindquist

Yumanity seeks to transform drug discovery for neurodegenerative diseases caused by protein misfolding.

January 21, 2015

Precision medicine in advanced colorectal cancer

If we truly want to see a more precision medicine approach evolve then we have to first find the oncogenic drivers. At ASCO GI one study in particular caught my eye and attention, but you won’t find it written up in the medical lay press and it’s not that obvious unless you know what you’re looking for.

January 20, 2015

How Syros are changing biotech R&D

Transcription factors are becoming a new buzzword in cancer research - why are they important for drug development?

January 15, 2015

bluebird bio CEO Nick Leschly seeks to make hope a reality

Bluebird bio is an emerging biotech company with a novel lentiglobin gene therapy in development that could revolutionize the treatment of beta-thalassemia and sickle cell disease.

January 14, 2015

Bellicum moves BPX-501 T Cell Therapy forward $BLCM

What's the vision for Bellicum Pharmaceuticals? In an in-depth interview CEO Tom Farrell and COO Annemarie Moseley discuss the benefits offered by their new products in development.

January 13, 2015

Will Bluebird Bio transform beta Thalassemia and Sickle Cell Anemia?

There is no available cure for patients with beta-thalassemia or sickle cell disease, but new developments are very encouraging

January 12, 2015

Biomarin PARP inhibitor talazoparib shows promise in gBRCA Breast Cancer

Biomarin have a good shot on goal with their PARP inhibitor talazoparib in gBRCA breast cancer

January 9, 2015

Next generation approaches to immuno-oncology – where next?

What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?

January 8, 2015

Cellectis ramps up CAR-T development in 2015

What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?

January 6, 2015

Targeting the unmet medical need in GvHD

Graft versus Host disease (GvHD) is an area of tremendous unmet medical need that is triggering the interest of a number of biotech and rare disease companies.

January 5, 2015

SABCS Update on Triple Negative Breast Cancer

In the last post of 2014, it’s time to address some pertinent questions on triple negative breast cancer (TNBC).

December 19, 2014

Do Checkpoint Inhibitors work in Triple Negative Breast Cancer?

There is a lot of interest in checkpoint inhibitors, do they look they will be effective in Triple Negative Breast Cancer?

December 10, 2014

ASH 2014 Day 3 Live blog #ASH14

"Manic Monday" at the annual meeting of the American Society of Hematology features multiple oral sessions run at the same time!

December 8, 2014

ASH 2014 Day 2 Live Blog #ASH14

Coverage of Day 2 of the annual meeting of the American Society of Hematology in San Francisco.

December 7, 2014

ASH 2014 Day 1 Live Blog #ASH14

It's Day 1 of the 2014 annual meeting of the American Society of Hematology meeting in San Francisco.

December 6, 2014

Top 10 AML abstracts at ASH 2014

There are a lot of new products in development for AML. Here's my top 10 abstracts to watch out for at ASH 2014 in San Francisco.

December 4, 2014

ASH 2014 Hodgkins Lymphoma and DLBCL Preview

Preview of ASH 2014 Key Abstracts in Lymphomas including HL and aggressive DLBCL

December 3, 2014

ASH 2014 Annual Meeting Multiple Myeloma Preview

ASH 2014 Multiple Myeloma data looks like it offers much promise for new treatments as well as an increasingly competitive marketplace

December 2, 2014

The Science of PD1 PDL1 Cancer Immunotherapy

The science of targeting PD-1 and it's ligand PD-L1 in cancer immunotherapy is highlighted in five Letters published in Nature this week.

November 26, 2014

EORTC Molecular Targets – new developments in Ovarian Cancer

Ovarian cancer has lagged behind other solid tumours in terms of development, but this situation may soon change with promising new agents being developed

November 19, 2014

Rociletinib versus AZD9291 race to market heats up in T790M lung cancer at EORTC

Clovis present their Phase 2 data with the new rociletinib formulation at EORTC-AACR-NCI in Barcelona

November 19, 2014

Agios IDH1 Inhibitor AG-120 shows promise in AML $AGIO

Agios AG-120 IDH1 Inhibitor shows promise in acute myeloid leukemia (AML) according to data to be presented at the EORTC-AACR-NCI Molecular Targets and Cancer Therapeutics Symposium in Barcelona

November 18, 2014

Targeting CD40 in Cancer Immunotherapy

How can we jumpstart the immune system to enable more patients to respond? At SITC we learned more about targeting CD40 to achieve this.

November 20, 2014

Can you reduce Graft versus Host Disease GvHD by regulating gut bacteria?

At the SITC 2014 annual meeting, Dr van den Brink presented data on how the bacteria in our gut (the intestinal microbiome) can impact GvHD.

November 18, 2014

Challenge of Cytokine Release Syndrome in CD19 CAR-T Cell Therapy

At the Society for Immunotherapy of Cancer (SITC) meeting last week, one of the Hot Topic sessions that took place after the conference formally ended was in managing the toxicities associated with chimeric antigen receptor T cell (CAR-T) therapy.

November 17, 2014

Will combining anti-OX40 with a checkpoint inhibitor matter in cancer?

OX40 could be an exciting new target in immune-oncology that could be combined with checkpoint inhibitors to improve the T cell response.

November 11, 2014

SITC 2014 Cancer Immunotherapy Day 1

Reflections on Day 1 of the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC).

November 8, 2014

SITC 2014 Cancer Immunotherapy Workshop Review

Day 1 of the SITC annual meeting started with two workshops on immunotherapy and combination therapy

November 7, 2014
Washington DC in Fall

SITC 2014 Cancer Immunotherapy Annual Meeting Preview

This week sees the start of the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD. We’re excited to be attending this meeting for the first time.

November 4, 2014

Immuno-Oncology Gems in the ESMO Poster Halls

There was a lot going on in lung, melanoma, renal and colorectal cancer in terms of immunotherapy in Madrid.

November 3, 2014

Update on PD1 checkpoint inhibition in lung cancer

Merck announced their Breakthrough therapy designation for Keytruda in lung cancer this morning. What did we learn from the updated data for checkpoint inhibitors in NSCLC at ESMO that was different from ASCO?

October 27, 2014

New therapies are emerging for the treatment of advanced stomach cancer

Checkpoint inhibitors are looking very promising in advanced gastric cancer

October 23, 2014

Potential of IDO as Immunotherapy Target

Genentech and NewLink announced a deal to license an IDO inhibitor. What's the impact of this on the IO pipeline?

October 20, 2014

ESMO Posters Highlight New Cancer Drugs in Development

Posters on new cancer drugs in development with novel targets were presented at ESMO 2014 Congress in Madrid.

October 15, 2014

New drug targets may change Colorectal Cancer Landscape

Advances in Metastatic Colorectal Cancer may come from new druggable targets according to ESMO 2014 CRC Symposium

October 13, 2014

ESMO 2014: Update on the ALK lung cancer market

How is the ALK+ lung cancer market developing now that there are multiple next generation competitors following on from Xalkori and Zykadia? Check out our analysis of the developing landscape...

October 9, 2014

Did Galeterone ARMOR2 Prostate Cancer Data Impress at ESMO 2014?

At ESMO 2014 Mary-Ellen Taplin, MD (Dana-Farber Cancer Institute) presented the results of the Tokai Pharmaceuticals ARMOR2 clinical trial of galeterone in men with advanced prostate cancer.

October 3, 2014

ESMO 2014 Cancer Congress Day 3 Live Blog

Day 3 of the live blog from the ESMO 2014 Cancer Congress in Madrid.

September 28, 2014

ESMO 2014 Live Blog Day 2 #ESMO14

Day 2 Live Blog with news and commentary on what's taking place at the ESMO Cancer Congress in Madrid

September 28, 2014

ESMO 2014 Cancer Congress Day 1 Live Blog

ESMO 2014 Cancer Congress data starts to roll out today - throughout the day we'll be updating the blog with initial impressions of data as it's presented.

September 27, 2014

ESMO 2014 Takes Off with Release of Oral Abstracts #ESMO14

Most of the abstracts for oral presentations at the forthcoming ESMO cancer congress in Madrid have just been released. This is a preview of some that caught my attention.

September 24, 2014

ESMO 2014 Scientific Symposia Preview

There are some interesting science symposia at #ESMO14 in both immunotherapy and targeted therapies. We review what the hot topics are here.

September 19, 2014

ESMO 2014 Poster Preview

A review of the key poster and poster discussion abstracts on immunotherapy and targeted therapies at ESMO 2014

September 18, 2014